

VerifyNow[®] Clinical Compendium

This VerifyNow Compendium includes peer-reviewed journal publications which will provide you with additional education on the effective use of VerifyNow Antiplatelet Testing, as well as support the value of ongoing use of testing in clinical practice.

Our goal is to provide you with knowledge of the vast number of clinical publications that have been completed using VerifyNow testing with antiplatelet medications such as clopidogrel (or other P2Y12 inhibitors), Aspirin or GP IIb/IIIa inhibitors such as abciximab, or eptifibatide.

Aspirin Test

..... Page 2

IIb/IIIa Test

..... Page 15

PRU/P2Y12 Test

..... Page 20

Supporting Clinical Guidelines

..... Page 53

Peer-Reviewed Publications Citing the VerifyNow Aspirin Test

- Abacı O, Kilickesmez KO.** Aspirin resistance: Where are we now? *Anadolu Kardiyol Derg.* 2013 Jun;13(4):370-3.
- Alstrom U, Granath F, Oldgren J, Stahle E, Tyden H, Siegbahn A.** Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. *Thromb Res.* 2009 Nov; 124(5):572-7.
- Amoah V, Smallwood A, Worrall AP, Lovatt T, Armesilla AL, Nevill AM, Cotton JM.** Poor aspirin response in diabetic patients presenting with acute coronary syndromes: results using a near patient test. *Thromb Res* 2011 Aug;128(2):196-9.
- Andersson T, Morrison D, Nagy P, Pisupati J, Schettler J, Warner TD.** Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. *Am J Cardiovasc Drugs.* 2012 Aug 1;12(4):217-24.
- Babcock MJ, Sane AC, Eckman DM, Sane DC.** Persistent erythema with niacin is not attributable to aspirin resistance. *J Clin Lipidol.* 2011 Mar-Apr;5(2):114-9.
- Bachelani AM, Bautz JT, Sperry JL, Corcos A, Zenati M, Billiar TR, Peitzman AB, Marshall GT.** Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury. *Surgery.* 2011 Oct;150(4):836-43.
- Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM.** A pilot study of resistance to aspirin in stroke patients. *J Clin Neurosci.* 2008 Nov;15(11):1204-9.
- Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG.** Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2. *Thromb Haemost.* 2009 Aug; 102(2):404-11.
- Bouman HJ, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM.** A case-control study on platelet reactivity in patients with coronary stent thrombosis. *J Thromb Haemost.* 2011 Jan;9(1):185-91.
- Breet NJ, Sluman MA, van Berkel MA, van Werkum JW, Bouman HJ, Harmsze AM, Kelder JC, Zijlstra F, Hackeng CM, Ten Berg JM.** Effect of gender difference on platelet reactivity. *Neth Heart J.* 2011 Nov;19(11):451-7.
- Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM.** High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. *Heart.* 2011 Jun;97(12):983-90.
- Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM.** High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. *J Thromb Haemost.* 2010 Oct; 8(10):2140-8.
- Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R.** Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. *Am J Cardiol.* 2007 Jun 1; 99(11):1518-22.
- Campo G.** Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). *J Am Coll Cardiol.* 2010 Jan 19;55(3):255-6.
- Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators.** Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. *J Am Coll Card* 2010 Oct 26;56(18):1447-55.
- Campo G, Fileti L, Valgimigli M, Marchesini J, Scalone A, Ferrari R.** Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. *J Blood Med.* 2010;1:61-9.

- Can MM, Tanboaya IH, Tarkyilmaz E, Karabay CY, Akgun T, Koca F, Tokgoz HC, Keles N, Ozkan A, Bezgin T, Ozveren O, Sonmez K, Saaylam M, Ozdemir N, Kaymaz C.** The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. *Thromb Res.* 2010 Apr;125(4):e132-7.
- Capodanno D, Patel A, Dharmashankar K, Ferreira JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ.** Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv.* 2011 Apr 1;4(2):180-7.
- Carroll RC, Craft RM, Snider CC, Aligeti VR, Wortham DC.** A comparison of VerifyNowR with PlateletMapping--detected aspirin resistance and correlation with urinary thromboxane. *Anesth Analg.* 2013 Feb;116(2):282-6.
- Cattaneo M.** The Role of Laboratory Monitoring in Antiplatelet Therapy in P. Gresele et al. (eds.), *Antiplatelet Agents, Handbook of Experimental Pharmacology* 210, DOI 10.1007/978-3-642-29423-5_19.
- Chen F, Maridakis V, O'neill EA, Beals C, Radziszewski W, de Lepeleire I, Van Dyck K, Depra M, Bolognese JA, de Hoon J, Jacquemin M.** A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel. *Platelets.* 2012;23(4):249-58.
- Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP.** Aspirin resistance and adverse clinical events in patients with coronary artery disease. *Am J Med.* 2007 Jul;120(7):631-5.
- Chen WH, Lee PY, Ng W, Kwok JY, Cheng X, Lee SW, Tse HF, Lau CP.** Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. *Am J Card.* 2005 Sep 15;96(6):760-3.
- Chen WH, Lee PY, Ng W, Tse HF, Lau CP.** Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol.* 2004 Mar 17;43(6):1122-6.
- Choi SW, Choi DH, Kim HW, Ku YH, Ha SI, Park G.** Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing. *Platelets.* 2013 Aug 2. doi: 10.3109/09537104.2013.821606 [Epub ahead of print].
- Cholette JM, Mamikonian L, Alfieris GM, Blumberg N, Lerner NB.** Aspirin resistance following pediatric cardiac surgery. *Thromb Res.* 2010 Sep;126(3):200-6.
- Chu JW, Wong CK, Chambers J, Wout JV, Herbison P, Tang EW.** Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. *QJM.* 2010 Jun;103(6):405-12.
- Coleman JL, Alberts MJ.** The effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. *Am J Cardiol.* 2006 Sep 15;98(6):838-41.
- Coleman JL, Wang JC, Simon DI.** Determination of individual response to aspirin therapy using the Accumetrics Ultegra RFPA-ASA system. *Point of Care.* 2004 June;3(2):77-82.
- Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monsegu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthelemy O, Beygui F, Silvain J, Vicaut E, Montalescot G, ARTIC Investigators.** Bedside monitoring to adjust antiplatelet therapy for coronary stenting. *N Engl J Med.* 2012 Nov 29;367(22):2100-9.
- Collins P, Ford I, Greaves M, Macauley E, Brittenden J.** Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state. *Platelets.* 2006 Aug;17(5):311-7.
- Coma-Canella I, Velasc A.** Variability in individual responsiveness to aspirin: clinical implications and treatment. Review. *Cardiovasc Hematol Disord Drug Targets.* 2007 Dec;7(4):274-87.

Consuegra-Sanchez L, Lopez-Palop R, Cano P, Carrillo P, Pico F, Villegas M, Sanchis J, Kaski JC. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. *J Thromb Haemost.* 2013 Feb;11(2):379-81.

Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, Barbato E, Bartunek J, De Bruyne B, Wijns W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. *Am J Card.* 2008 Jun 15;101(12):1700-3.

Dawson J, Quinn T, Lees KR, Walters MR. Microembolic signals and aspirin resistance in patients with carotid stenosis. *Cardiovasc Ther.* 2012 Aug;30(4):234-9.

Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, Walters MR. Aspirin Resistance and Compliance with Therapy. *Cardiovasc Ther.* 2011 Oct;29(5):301-7.

Dharmasaroja PA, Sae-Lim S. Comparison of Aspirin Response Measured by Urinary 11-Dehydrothromboxane B2 and VerifyNow Aspirin Assay in Patients with Ischemic Stroke. *J Stroke Cerebrovasc Dis.* 2013 Oct 11. doi:pii: S1052-3057(13)00330-3. 10.1016/j.jstrokecerebrovasdis.2013.08.001. [Epub ahead of print].

DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. *Diabetes.* 2007 Dec;56(12):3014-9.

Dichiara J, Bliden KP, Tantry US, Chaganti SK, Kreutz RP, Gesheff TB, Kreutz Y, Gurbel PA. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. *Platelets.* 2007 Sep;18(6):414-23.

Divani AA, Zantek ND, Borhani-Haghighi A, Rao GHR. Antiplatelet Therapy: Aspirin Resistance and All That Jazz! *Clin Appl Thromb Hemost* 2013 19:5.

Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. *Ann Pharmacother.* 2007 May;41(5):737-41.

Dyszkiewicz-Korpanty AM, Kim A, Burner JD, Frenkel EP, Sarode R. Comparison of a rapid platelet function assay – Verify Now Aspirin – with whole blood impedance aggregometry for the detection of aspirin resistance *Thromb Res.* 2007;120(4):485-8.

El-Atat F, Sarkar K, Kodali V, Karajgikar R, Jakkulla M, Mares A, Sharma S, Kini A. A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention. *J Invasive Cardiol* 2011 Jan;23(1):9-13. Response by Dieter published.

Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, Berg JM, Hackeng CM. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. *Thromb Haemost* 2009;102(4):719-727.

Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Papp E, Szapary L, Kesmarky G, Toth K. Clinical importance of aspirin and clopidogrel resistance. *World J Cardiol.* 2010 Jul 26;2(7):171-86.

Ferreiro JL, Homs S, Berdejo J, Roura G, Gomez-Lara J, Romaguera R, Teruel L, Sanchez-Elvira G, Marcano AL, Gomez-Hospital JA, Angiolillo DJ, Cequier A. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. *Thromb Haemost.* 2013 Jul 1;110(1):110-7.

Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. *J Thromb Haemost.* 2006 Apr;4(4):813-9.

- Fontana P, Reber G, de Moerloose P.** Assessing aspirin responsiveness using the Verify Now Aspirin assay. *Thromb Res.* 2008;121(4):581-2.
- Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD.** Aspirin "resistance": role of pre-existent platelet reactivity and correlation between tests. *J Thromb Haemost.* 2008 Dec;6(12):2035-44.
- Funck-Jensen KL, Dalsgaard J, Grove EL, Hvas AM, Kristensen SD.** Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. *Platelets.* 2013;24(7):528-37.
- Garcia-Rinaldi R, Carro-Pagan C, Schaff HV, McKellar SH, Thompson JL 3rd, Quinones J, Rodriguez-Acosta JF.** Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses. *J Heart Valve Dis.* 2009 Nov;18(6):617-25; discussion 626.
- Gasparyan AY.** Aspirin and clopidogrel resistance: methodological challenges and opportunities. *Vasc Health Risk Manag.* 2010;6 109-112.
- Geara AS, Azzi N, Bassil C, El-Sayegh S.** Aspirin resistance in hemodialysis patients. *Int Urol Nephrol* 2012 Feb;44(1):323-5.
- Glauser J, Emerman CL, Bhatt DL, Peacock WF.** Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. *Am J Emerg Med.* 2010 May;28(4):440-4.
- Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, McNicholas KW, Segal JB, Rade JJ.** Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. *J Am Coll Cardiol.* 2011 Mar 1;57(9):1069-77.
- Gremmel T, Kopp CW, Seidinger D, Giurgea GA, Koppensteiner R, Steiner S, Panzer S.** The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists-inducible platelet reactivity. *Atherosclerosis.* 2009 Dec;207(2):608-13.
- Gremmel T, Mueller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, Panzer S.** Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. *Nephrol Dial Transplant.* 2013 Aug;28(8):2116-22.
- Gremmel T, Panzer S, Steiner S, Seidinger D, Koppensteiner R, Pabinger I, Kopp CW, Ay C.** Response to antiplatelet therapy is independent of endogenous thrombin generation potential. *Thromb Res.* 2013 Jul;132(1):e24-30.
- Gremmel T, Perkmann T, Seidinger D, Koppensteiner R, Panzer S, Kopp CW, Steiner S.** Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. *J Atheroscler Thromb.* 2013 Jul 30;20(7):630-45.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. *Thromb Res.* 2009 Nov;124(5):588-91.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. *Platelets.* 2011;22(3):188-95.
- Grinstein J, Cannon CP.** Aspirin Resistance: Current Status and Role of Tailored Therapy. *Clin Cardiol* 2012 Nov;35(11):673-81.
- Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA.** Drug resistance and pseudo-resistance: an unintended consequence of enteric coating aspirin. *Circulation.* 2013 Jan 22;127(3):377-85.
- Grove EL.** Antiplatelet effect of aspirin in patients with coronary artery disease. Review. *Dan Med J.* 2012 Sep;59(9):B4506.
- Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD.** Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. *J Thromb Haemost.* 2011 Jan;9(1):185-91.

Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. *Thromb Haemost.* 2010 Jun;103(6):1245-53.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. *Circulation.* 2007 Jun 26;115(25):3156-64.

Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. *Platelets.* 2008 Mar;19(2):119-24.

Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. *Stroke* 2005 May;36(5):1001-5.

Hezard N, Tessier-Marteau A, Macchi L. New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine. Review. *Cardiovasc Hematol Disord Drug Targets.* 2010 Sep 1;10(3):224-33.

Hobson AR, Petley G, Morton G, Dawkins KD, Curzen NP. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with drug-eluting stent thrombosis whilst on dual antiplatelet therapy. *Thromb J.* 2008 Feb 29;6:1.

Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. *Am Heart J.* 2007 Feb;153(2):175-81.

Huczek Z, Filipiak KJ, Kochman J, Michalak M, Grabowski M, Opolski G. Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. *J Thromb Thrombolysis.* 2013 Jul;36(1):22-30.

Huczek Z, Filipiak KJ, Kochman J, Michalak M, Roik M, Piatkowski R, Grabowski M, Postula M, Opolski G. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. *Thromb Res.* 2010 May;125(5):406-12.

Jeon SB, Song HS, Kim BJ, Kim HJ, Kang DW, Kim JS, Kwon SU. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. *Eur Neurol.* 2010;64(1):51-7.

Jeong YH, Park Y, Bliden KP, Tantry US, Gurbel PA. High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. *Heart* 2012;98:343.

Jesurum JT, Fuller CJ, Murinova N, Truva CM, Lucas SM. Aspirin's effect on platelet inhibition in migraineurs. *Headache.* 2012 Sep;52(8):1207-18.

Joseph B, Pandit V, Sadoun M, Larkins CG, Kulvatunyou N, Tang A, Mino M, Friese RS, Rhee P. A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage. *J Trauma Acute Care Surg.* 2013 Dec;75(6):990-4.

Kang DY, Yang HM, Park KW, Lee SR, Lee MH, Lee DW, Lee HY, Kang HJ, Koo BK, Chae IH, Choi DJ, Kim HS, Kim CH. Lack of association between low density lipoprotein particle size and on-treatment platelet reactivity in patients with coronary artery disease. *Korean Circ J.* 2012 Aug;42(8):551-7.

Kaplon-Cieslicka A, Rosiak M, Postula M, Serafin A, Kondracka A, Opolski G, Filipiak KJ. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. *Kardiol Pol.* 2013;71(9):893-902.

- Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL.** Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. *Am Heart J.* 2006 May;151(5):976.e7-11.
- Karnabatidis D, Spiliopoulos S, Pastromas G, Kitrou P, Christeas N, Katsanos K, Siablis D.** Prevalence of Nonresponsiveness to Aspirin in Patients with Symptomatic Peripheral Arterial Disease Using True Point of Care Testing. *Cardiovasc Intervent Radiol.* 2013 Aug 1. doi 10.1007/s00270-013-0710-3 [Epub ahead of print].
- Karon BS, Wockenfus A, Scott R, Hartman SJ, McConnell JP, Santrach PJ, Jaffe AS.** Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. *Clin Chem.* 2008 Jun;54(6):1060-5.
- Kasmeridis C, Apostolakis S, Lip GYH.** Aspirin and aspirin resistance in coronary artery disease. *Curr Opin Pharmacol.* 2013 Apr;13(2):242-50.
- Kim BJ, Lee SW, Park SW, Kang DW, Kim JS, Kwon SU.** Insufficient platelet inhibition is related to silent embolic cerebral infarctions after coronary angiography. *Stroke.* 2012 Mar;43(3):727-32.
- Kim BK, Oh SJ, Yoon SJ, Jeon DW, Ko YG, Yang JY.** A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. *Yonsei Med J.* 2011 Sep;52(5):717-26.
- Kim H, Lee HK, Han K, Jeon HK.** Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. *Ann Clin Lab Sci.* 2009 Summer;39(3):289-94.
- Kim HJ, Lee JM, Seo JH, Kim JH, Hong DM, Bahk JH, Kim KB, Jeon Y.** Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery. *J Korean Med Sci.* 2011 Aug;26(8):1041-6.
- Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH.** Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. *Circ J.* 2007 Dec;71(12):1867-72.
- Kim KE, Woo KS, Goh RY, Quan ML, Cha KS, Kim MH, Han JY.** Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. *Int J Lab Hematol.* 2010 Feb;32(1 PT 2):50-5.
- Kim SA, Lim SY.** A case of stent thrombosis occurred at 5 years after sirolimus-eluting stent implantation. *Chonnam Med J.* 2011 Aug;47(2):124-6.
- Kinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O'Neill D, Murphy RP, McCabe DJ.** Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100 and VerifyNow. *J Stroke Cerebrovasc Dis.* 2013 Oct;22(7):e84-92.
- Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, Hong MK, Seo MK, Youn TJ, Chae IH, Choi DJ, Jang Y.** Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. *Am Heart J.* 2011 Feb;161(2):383-90.
- Kovacs EG, Katona E, Bereczky Z, Homoradi N, Balogh L, Toth E, Peterfy H, Kiss RG, Edes I, Muszbek L.** Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. *Thromb Res.* 2013 Oct 16. doi:pii: S0049-3848(13)00478-7. 10.1016/j.thromres.2013.10.008. [Epub ahead of print].
- Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR.** Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. *BMJ.* 2008 Jan 26;336(7637):195-8.
- Kuzniatsova N, Shantsila E, Blann A, Lip GYH.** A contemporary viewpoint on ' aspirin resistance '. *Annals of Medicine,* 2012; 44: 773–783.

Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. *Thromb Haemost.* 2013 May;109(5):920-9.

Larsen SB, Neergaard-Petersen S, Grove EL, Kristensen SD, Hvas AM. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. *Thromb Haemost.* 2012 Jul;108(1):140-7.

Leadbeater PD, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, Mitchell JA, Warner TD. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. *J Thromb Haemost.* 2011 Oct;9(10):2050-6.

Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. *Am J Neuroradiol.* 2008 Aug;29(7):1389-94.

Lee DH, Kim HS, Kim SM, Kwon SU, Suh DC. Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting. *Neurointervention.* 2012 Feb;7(1):23-6.

Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. *Eur J Neurol.* 2010 Mar;17(3):434-42.

Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, Lau CP. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *Am J Med.* 2005 Jul;118(7):723-7.

Lee YK, Kim HS, Park JY, Kang HJ. Incidence of aspirin resistance in the patient group of a university hospital in Korea. *Korean J Lab Med.* 2008 Aug;28(4):251-7. Note: Article is in Korean, Abstract available on PubMed in English.

Lee SP, Park KW, Shin DH, Lee HY, Kang HJ, Koo BK, Suh JW, Youn TJ, Choi DJ, Chae IH, Kim HS. Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy. *J Atheroscler Thromb.* 2011;18(10):914-23.

Lemkes BA, Bahler L, Kamphuisen PW, Stroobants AK, Van Den Dool EJ, Hoekstra JB, Nieuwland R, Gerdes VE, Holleman F. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. *J Thromb Haemost.* 2012 Apr;10(4):639-46.

Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. *J Am Coll Cardiol.* 2010 Jan 12;55(2):114-21.

Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. *J Am Coll Cardiol.* 2006 Jan 3;47(1):27-33.

Liew YP, Fissell R, Bhatt D, Kottke-Marchant K, Heyka R. Accuracy and reliability of point-of-care platelet assays in hemodialysis patients. *Interv Cardiol* 2011;3(4):515-20.

Lordkipanidze M. Advances in monitoring of aspirin therapy. Review. *Platelets.* 2012;23(7):526-36.

Lordkipanidze M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease. *Am J Cardiol.* 2009 Nov 1;104(9):1189-93.

Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. *Eur Heart J.* 2007 Jul;28(14):1702-8.

Luchessi AD, Silbiger VN, Hirata RD, Lima-Neto LG, Cavichioli D, Iniguez A, Bravo M, Bastos G, Sousa AG, Brión M, Carracedo A, Hirata MH. Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients. *Clin Chim Acta.* 2013 Oct 21;425:9-17.

- Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E.** Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. *Clin Chem.* 2010 May;56(5):839-47.
- Mangiaca F, Peace AJ, Wijns W, Barbato E.** Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. *J Thromb Thrombol.* 2011 Jul;32(1):54-8.
- Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V.** Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. *Blood Coagul Fibrinolysis.* 2004;15(4):295-301.
- Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL.** Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. *Eur J Pharmacol.* 2003 Feb 21;462(1-3):139-43.
- Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C.** Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study. *Heart.* 2012 Dec;98(23):1710-5.
- McGlasson DL, Fritsma GA.** Comparison of four laboratory methods to assess aspirin sensitivity. *Blood Coagul Fibrinolysis.* 2008 Mar;19(2):120-3.
- Mehta J, Mohandas B.** Aspirin resistance: Fact or fiction? A point of view. *World J Cardiol* 2010 September 26; 2(9): 280-288.
- Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB.** Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. *Am J Cardiol.* 2006;97(4):567-70.
- Michalak M, Huczek Z, Filipiak KJ, Roik MF, Kochman J, Opolski G.** Periprocedural myocardial damage during percutaneous coronary intervention: a point-of-care platelet testing and intravascular ultrasound/virtual histology study. *Kardiol Pol.* 2013;71(4):325-33.
- Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM.** Clinical consequences of aspirin and clopidogrel resistance: an overview. *Acta Neurol Scand.* 2013 Oct;128(4):213-9.
- Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M.** Frequency of aspirin resistance in a community hospital. *Am J Cardiol.* 2006; Sep 1;98(5):577-9.
- Moceri P, Doyen D, Cerboni P, Ferrari E.** Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. *Thromb Res.* 2011 Nov;128(5):458-62.
- Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM.** Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. *Thromb Res.* 2010 Oct;126(4):e318-22.
- Muller O, Hamilos M, Bartunek J, Ulrichs H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercausse K, de Bruyne B, Wijns W, Barbato E.** Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol.* 2010 Feb 1;105(3):333-8.
- Naidech AM, Bassin SL, Bernstein RA, Batjer HH, Alberts MJ, Lindholm PF, Bleck TP.** Reduced Platelet Activity is More Common than Reported Anti-Platelet Medication Use in Patients with Intracerebral Hemorrhage. *Neurocrit Care.* 2009 Dec;11(3):307-10.
- Naidech AM, Bendok BR, Garg RK, Bernstein RA, Alberts MJ, Bleck TP, Batjer HH.** Reduced platelet activity is associated with more intraventricular hemorrhage. *Neurosurgery.* 2009 Oct;65(4):684-8.

- Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, Bernstein RA, Alberts MJ, Batjer HH.** Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. *Stroke* 2009 Jul;40(7):2398-401.
- Naidech AM, Liebling SM, Rosenberg NF, Lindholm PF, Bernstein RA, Batjer HH, Alberts MJ, Kwaan HC.** Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. *Neurocrit Care*. 2012 Feb;16(1):82-7.
- Neergaard-Petersen S, Ajjan R, Hvas AM, Hess K, Larsen SB, Kristensen SD, Grove EL.** Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. *PLoS One*. 2013 Aug 19;8(8):e71150.
- Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, Hvas AM.** Aspirin response evaluated by the VerifyNow® Aspirin System and Light Transmission Aggregometry. *Thromb Res*. 2008;123(2):267-73.
- Nishino M, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T.** Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment. *Digestion*. 2013;88(2):79-86.
- Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben T.** Aspirin resistance in patients with acute ischemic stroke. *J Neurol*. 2011 Nov;258(11):1979-86.
- Ozben B, Tanrikulu AM, Ozben T, Caymaz O.** Aspirin resistance in hypertensive patients. *J Clin Hypertens (Greenwich)*. 2010 Sep;12(9):714-20.
- Paniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E, Valente S, Giglioli C, Fedi S, Gensini GF, Abbate R, Prisco D.** Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. *Am J Clin Pathol*. 2007;128:143-149.
- Park J, Shin DH, Kim BK, Her AY, Kim YH, Choi HH, Kim JS, Ko YG, Choi D, Jang Y, Hong MK.** Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation. *Eur Heart J Cardiovasc Imaging*. 2013 Dec;14(12):1181-6.
- Park SH, Kim YB, Huh SK.** Effect of premedication method and drug resistance of antiplatelet agent on periprocedural thromboembolic events during coil embolization of an unruptured intracranial aneurysm. *J Cerebrovasc Endovasc Neurosurg*. 2012 Sep;14(3):148-56.
- Park SJ, Oh IY, Kim KH, Shin DH, Yang HM, Lee HY, Koo BK.** Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. *Int J Cardiol*. 2011 Jun 2;149(2):e85-7.
- Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C.** Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood*. 2012 Apr 12;119(15):3595-603.
- Postula M, Janicki PK, Rosiak M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Filipiak KJ, Kosior DA, Czlonkowski A, Opolski G.** Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes. *Med Sci Monit*. 2013 May 27;19:394-408.
- Postula M, Janicki PK, Rosiak M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Filipiak KJ, Kosior DA, Czlonkowski A, Opolski G.** New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: genome-wide association approach and pooled DNA strategy. *J Thromb Thrombolysis*. 2013 Jul;36(1):65-73.

Postula M, Janicki PK, Rosiak M, Przybylkowski A, Kaplon-Cieslicka A, Grygorowicz T, Trzepla E, Filipiak KJ, Czlonkowski A, Opolski G. Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients. *Cardiol J.* 2013;20(2):170-7.

Postula M, Kaplon-Cieslicka A, Rosiak M, Kondracka A, Serafin A, Filipiak KJ, Czlonkowski A, Opolski G, Janicki PK. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. *J Thromb Haemost.* 2011 Nov;9(11):2291-301.

Postula M, Rosiak M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Filipiak KJ, Czlonkowski A, Opolski G. Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes? *Cardiol J.* 2012;19(5):494-500.

Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. *Am J Neuroradiol.* 2008 Feb;29(2):281-5.

Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, Papp E, Lupkovics G, Szapary L. Aspirin resistance: focus on clinical endpoints. Review. *J Cardiovasc Pharmacol.* 2008 Dec;52(6):475-84.

Rajendran S, Parikh D, Shugman I, French JK, Juergens CP. High on treatment platelet reactivity and stent thrombosis. *Heart Lung Circ.* 2011 Aug;20(8):525-31.

Rollini F, Tello-Montoliu A, Angiolillo DJ. Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. *Platelets.* November 2012; 23(7): 537-551.

Rosiak M, Postula M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Zaremba M, Filipiak KJ, Kosior DA, Czlonkowski A, Opolski G, Janicki PK. Lack of effect of common single nucleotide polymorphisms in leukotriene pathway genes on platelet reactivity in patients with diabetes. *Mol Med Rep.* 2013 Sep;8(3):853-60.

Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E, Filipiak KJ, Czlonkowski A, Opolski G. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. *Kardiologia Pol.* 2013;71(6):552-7.

Ryu DS, Hong CK, Sim YK, Kim CH, Jung JY, Joo JY. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. *J Korean Neurosurg Soc.* 2010 Oct;48(4):319-24.

Sambu N, Hobson A, Curzen N. "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility. *Platelets.* 2011;22(3):210-6.

Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattini G, Dava G, Patrono C. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". *J Am Coll Cardiol.* 2009 Feb 24;53(9):667-77.

Sarode R, Frenkel E. And, more on: assessing aspirin responsiveness using the Verify now aspirin assay. *Thromb Res.* 2008;121(4):587-8.

Saw J, Densem C, Walsh S, Jokhi P, Starovoytov A, Fox R, Wong G, Buller C, Ricci D, Mancini GB, Fung A. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: A BRIEF-PCI (Brief Infusion of Intravenous Eptifibatid Following Successful Percutaneous Coronary Intervention) Trial Substudy. *J Am Coll Cardiol Intv.* 2008 Dec;1:654-59.

Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. *J Am Coll Cardiol.* 2008 Dec 2;52(23):1826-33.

Scheinowitz M, Pakala R, Ben-Dor I, Lemesle G, Torguson R, Pichard AD, Lindsay J, Waksman R. Platelet reactivity in diabetic patients subjected to acute exercise stress test. *Cardiovasc Revasc Med.* 2011 Jan-Feb;12(1):20-4.

- Schorr K, Huber K, Hohlfeld T.** Functional Testing Methods for the Antiplatelet Effects of Aspirin. *Biomarkers Med.* 2011;5(1):31-42.
- Schulman SP.** Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. *JAMA.* 2004 Oct 20;292(15):1875-82.
- Seok JI, Joo IS, Yoon JH, Choi YJ, Lee PH, Huh K, Bang OY.** Can aspirin resistance be clinically predicted in stroke patients? *Clin Neurol Neurosurg.* 2008 Feb;110(2):110-6.
- Serebruany VL, Malinin AI, Bhatt DL.** Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? *Am J Med.* 2006 Aug;119(8):707.e11-6.
- Serebruany VL, Malinin AI, Oshrine BR, Sane DC, Takserman A, Atar D, Hennekens CH.** Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. *Thromb Res.* 2004;113(3-4):197-204.
- Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF.** Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. *Am Heart J.* 2008 Jan;155(1):93.e1-7. Comment in: *Am Heart J.* 2008 Jun;155(6):e47; author reply e49.
- Serebruany VL, Malinin AL, Pokov AN, Hanley DF.** Antiplatelet Profiles of the Fixed-Dose Combination of Extended-Release Dipyridamole and Low-Dose Aspirin Compared with Clopidogrel With or Without Aspirin in Patients with Type 2 Diabetes and a History of Transient Ischemic Attack: A Randomized, Single Blind, 30-Day Trial. *Clinical Therapeutics.* 2008 30(2):249-59.
- Shim CY, Yoon SJ, Park S, Kim JS, Choi JR, Ko YG, Choi D, Ha JW, Jang Y, Chung N, Shim WH, Cho SY.** The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. *Int J Cardiol.* 2009 May 29;134(3):351-5.
- Simpson SH, Abdelmoneim AS, Omran D, Featherstone T.** Prevalence of High on-Treatment Platelet Reactivity in Diabetic Patients Treated with Aspirin. *Am J Med.* 2013 Oct 8 doi: 10.1016/j.amjmed.2013.09.019 [Epub].
- Slottow TLP, Bonello L, Gavini R, Beauzile P, Sushinsky SJ, Scheinowitz M, Kaneshige K, Xue Z, Torguson R, Tantry U, Pichard AD, Satler LF, Suddath WO, Kent K, Gurbel P, Waksman R.** Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. *Am J Cardiol* 2009;104:525-530.
- Smock K, Rodgers G.** Laboratory evaluation of aspirin responsiveness. *Am J Hematol.* 2010 May;85(5):358-60.
- Song TJ, Suh SH, Min PK, Kim DJ, Kim BM, Heo JH, Kim YD, Lee KY.** The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting. *Yonsei Med J.* 2013 Mar 1;54(2):288-94.
- Stegnar M.** Platelet function tests and resistance to antiplatelet therapy. Review. *Srp Arh Celok Lek.* 2010 Jan;138 Suppl 1:59-63.
- Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators.** Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet.* 2013 Aug 17;382(9892):614-23.
- Suh JW, Kim SY, Park JS, Kim YS, Kang HJ, Koo BK, Kim HS.** Comparison of triple antiplatelet therapy including triflusal and conventional dual therapy in patients who underwent drug-eluting stent implantation. *Int Heart J* 2009; 50:701-709.
- Sun W, Gerhardinger C, Dagher Z, Hoehn T, Lorenzi M.** Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. *Diabetes.* 2005 Dec;54(12):3418-26 (Note: Study is in rats with customized test cartridge).

- Swaim L, Hillman RS.** Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study. *J Thromb Thrombolysis*. 2009 Jul;28(1):94-100.
- Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O.** Aspirin resistance in patients with chronic renal failure. *J Nephrol*. 2011 Sep-Oct;24(5):636-46.
- Taylor G, Osinski D, Thevenin A, Devys JM.** Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? *J Trauma Acute Care Surg*. 2013 May;74(5):1367-9.
- Vaduganathan M, Alviar CL, Arikan ME, Tellez A, Guthikonda S, DeLao T, Granada JF, Kleiman NS, Ballantyne CM, Lev EI.** Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. *Am Heart J*. 2008 Nov;156(5):1002.e1-1002.e7.
- Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabate M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R, 3T/2R Investigators.** Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. *Circulation*. 2009 Jun 30;119(25):3215-22.
- van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM.** The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. *Platelets*. 2008 Nov;19(7):479-88.
- Vaturi M, Vaduganathan M, Bental T, Solodky A, Kornowski R, Lev EI.** Relation of aspirin response to age in patients with stable coronary artery disease. *Am J Cardiol*. 2013 Jul 15;112(2):212-6.
- Viswanathan GN, Marshall SM, Schechter CB, Balasubramaniam K, Badimon JJ, Zaman AG.** Thrombus and antiplatelet therapy in type 2 diabetes mellitus: A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. *Thromb Haemost*. 2012 Nov;108(5):937-45.
- Voorra D, Cyr D, Lucas J, Chi JT, Dungan J, McCaffrey TA, Katz R, Newby LK, Kraus WE, Becker RC, Ortel TL, Ginsburg GS.** Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. *J Am Coll Cardiol*. 2013 Oct 1;62(14):1267-76.
- Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, Simon DI.** Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. *Am J Cardiol*. 2003 Dec 15;92(12):1492-4.
- Woo KS, Kim BR, Kim JE, Goh RY, Yu LH, Kim MH, Han JY.** Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests. *Korean J Lab Med* 2010;30:460-8.
- Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD.** Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. *JACC Cardiovasc Interv*. 2010 Aug;3(8):828-35.
- Wurtz M, Hvas AM, Kristensen SD, Grove EL.** Platelet aggregation is dependent on platelet count in patients with coronary artery disease. *Thromb Res*. 2012 Jan;129(1):56-61.
- Wurtz M, Hvas AM, Wulff LN, Kristensen SD, Grove EL.** Shear-induced platelet aggregation in aspirin-treated patients: initial experience with the novel PlaCor PRT device. *Thromb Res*. 2012 Nov;130(5):753-8.
- Wurtz M, Wulff LN, Grove EL, Kristensen SD, Hvas AM.** Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. *Thromb Res*. 2012 Apr;129(4):434-40.

Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Clinical determinants of aspirin resistance in diabetes. *Diabetes Res Clin Pract.* 2010 Oct;90(1):e19-21.

Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Effect of glucose or fat challenge on aspirin resistance in diabetes. *Int J Endocrinol.* 2010;2010:820876.

Yu LH, Kim MH, Zhang HZ, Park JS, Park TH, Kim YD, Cha KS, Han JY. Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome. *Korean Circ J.* 2012 Jun;42(6):382-9.

Zhang HZ, Yu LH, Kim MH. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin. *Platelets.* 2013;24(5):339-47.

Zheng AS, Churilov L, Colley RE, Goh C, Davis SM, Yan B. Association of aspirin resistance with increased stroke severity and infarct size. *JAMA Neurol.* 2013 Feb;70(2):208-13.

Peer-Reviewed Publications Citing the VerifyNow IIb/IIIa Test

Ainiding G, Yamashita K, Torii T, Furuta K, Isobe N, Matsushita T, Masaki K, Matsumoto S, Kira J. Clinical disability progression and platelet GP IIb/IIIa values in patients with atopic myelitis. *J Neuroimmunol.* 2012 May 15;246(1-2):108-12.

Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials. *J Thromb Thrombolysis.* 2002 Dec;14(3):197-203.

Casterella PJ, Kereiakes DJ, Steinhubl SR, Raymond RE, Kottke-Marchant K, Patel K, Mueller M, Rosenthal M, Moliterno DJ, Teirstein PS. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. *Catheter Cardiovasc Interv.* 2001 Dec;54(4):497-504.

Choi DH, Suh JW, Park KW, Kang HJ, Kim HS. Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: a prospective, open-label, randomized, controlled study in Korean patients. *Clin Ther.* 2009 Aug;31(8):1804-11.

Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. *J Cardiovasc Pharmacol Ther.* 2009 Sep;14(3):157-69.

Collet JP, van Werkum JW. Individualised Antiplatelet Therapy – Is There a Role for Platelet Function Testing in Routine Clinical Practice? *European Cardiol.* 2010;6(1):41-9

Collins P, Ford I, Greaves M, Macauley E, Brittenden J. Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state. *Platelets.* 2006 Aug;17(5):311-7.

Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. *Am J Cardiol.* 2006 Feb 15;97(4):489-93.

Danzi GB, Capuano C, Sesana M, Baglini R. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. *Curr Med Res Opin.* 2003;19(1):28-33.

Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatid and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. *Am Heart J.* 2004 Apr;147(4):E17.

Dupont AG, Gabriel DA, Cohen MG. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. *Thrombosis Research.* 2009;124(1):6-13.

Freedman J, Mascelli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR. Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects. *Am Heart J.* 2002 Jan;143(1):87-94.

Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, Michelson AD. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. *Am Heart J.* 2003 Feb;145(2):e6.

Gachet C, Aleil B. Testing antiplatelet therapy. *European Heart Journal Supplements* 2008;10(Supplement A), A28-A34.

Geisler T, Gawaz M, Steinhubl S, Bhatt D, Storey R, Flather M. Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? *Pharmacol Ther.* 2010 Aug;127(2):95-107.

Gibbs NM. Point-of-care assessment of antiplatelet agents in the perioperative period: a review. *Anaesth Intensive Care.* 2009 May;37(3):354-69.

- Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD.** Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol.* 2007 Nov 6;50(19):1822-34.
- Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lusche W, Breddin HK.** In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. *Thromb Res.* 2001 Apr 1;102(1):39-48.
- Hofer CK, Zollinger A, Ganter MT.** Perioperative assessment of platelet function in patients under antiplatelet therapy. *Expert Rev Med Devices.* 2010 Sep;7(5):625-37.
- Johns CS.** Platelet Function Testing. *Clinical Hemostasis Review* 2004;18(4)1-8.
- Kereiakes DJ, Broderick TM, Roth EM, Whang D, Mueller M, Lacock P, Anderson LC, Howard W, Blanck C, Schneider J, Abbottsmith CA.** High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. *J Thromb Thrombolysis.* 2000 Feb;9(2):149-55.
- Kereiakes DJ, Broderick TM, Roth EM, Whang D, Shimshak T, Runyon JP, Hattemer C, Schneider J, Lacock P, Mueller M, Abbottsmith CW.** Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol.* 1999 Aug 15;84(4):391-5.
- Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Whang DD, Abbottsmith CW.** Efficacy of abciximab induced platelet blockade using a rapid point of care assay. *J Thromb Thrombolysis.* 1999 Jun;7(3):265-76.
- Kini AS, Richard M, Suleman J, Perez N, Lee P, Fisher EA, Kamran M, Marmur JD, Sharma SK.** Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). *Am J Cardiol.* 2002 Sep 1;90(5):526-9.
- Kralisz P, Dobrzycki S, Nowak K, Kochman W, Gajewska-Bachorzewska H, Gugala K, Mezynski G, Prokopczuk P, Zuk J, Korecki J, Poniatowski B, Musiał W.** Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction. *Kardiol Pol.* 2004 May;60(5):459-67.
- Lakkis N, Lakiss N, Bobek J, Farmer J.** Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited. *Catheter Cardiovasc Interv.* 2002 Aug;56(4):474-7.
- Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M.** Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. *Review. Biomark Med.* 2011 Feb;5(1):63-70.
- Mardikar HM, Hiremath MS, Moliterno DJ, Mathew R, Arora R, Deo D, Hiremath JS, Deshpande NV, Khan A, Joseph J, Mukherjee D.** Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. *Am Heart J.* 2007 Aug;154(2):344.e1-5.
- Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Voss R.** Comparison of GP IIB/IIIa inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. *J Thromb Thrombolysis.* 2001 Oct;12(2):129-39.
- Michelson AD.** Methods for the measurement of platelet function. *Review. Am J Cardiol.* 2009 Feb 2;103(3 Suppl):20A-26A.
- Michelson AD.** Platelet function testing in cardiovascular diseases. *Circulation.* 2004 Nov 9;110(19):e489-93
- Mukherjee D, Chew DP, Robbins M, Yadav JS, Raymond RE, Moliterno DJ.** Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. *J Thromb Thrombolysis.* 2001 Apr;11(2):151-4.

Mukherjee D, Moliterno DJ. Applications of anti-platelet monitoring in catheterization laboratory. *J Thromb Thrombolysis*. 2000 Apr;9(3):293-301.

Mukherjee D, Moliterno DJ. Monitoring antiplatelet therapy: What is the best method? *Clin Pharmacokinet*. 2000 Dec;39(6):445-58.

Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatid in patients undergoing coronary stenting. *J Am Coll Cardiol*. 2001 Apr;37(5):1323-8.

Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK. Assessment of platelet function assays. *Am Heart J*. 1998 May;135(5 Pt 2 Su):S170-8.

Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. *Circulation*. 2001 Mar 20;103(11):1488-91.

Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Review. *Cardiovasc Revasc Med*. 2011 Sep-Oct;12(5):312-22.

Paniccia R. Platelet Function Testing in High-risk Coronary Artery Disease Patients – An Update. Review. *US Cardiology*, 2009;6(1):75-80.

Perez de Prado A, Fernández-Vazquez F, Cuellas JC, Alonso-Orcajo N, Carbonell R, Pascual C, Olalla C, Diego A, de Miguel A, Calabozo RG. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST- elevation acute myocardial infarction treated by primary percutaneous coronary intervention. *Am J Cardiol*. 2006 Mar 15;97(6):798-803.

PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integridin Cost Evaluation (PRICE) Trial. *Am Heart J*. 2001 Mar;141(3):402-9.

Price MJ, Berger PB, Angiolillo DJ, Tierstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. *Am Heart J* 2009;157:818-824.e1.

Quinn MJ, et al. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. *J Pharmacol Exp Ther*. 2001 May;297(2):496-500.

Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. *J Invasive Cardiol*. 2010 Jan;22(1):2-6.

Selvaraj CL, Van de Graaff EJ, Campbell CL, Abels BS, Marshall JP, Steinhubl SR. Point-of-care determination of baseline platelet function as a predictor of clinical outcomes in patients who present to the emergency department with chest pain. *J Thromb Thrombol*. 2004 Oct;18(2):109-15.

Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. *Pharmacol Res*. 2001 May;43(5):453-62.

Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? *Am J Med*. 2006 Aug;119(8):707.e11-6.

- Serebruany VL, Malinin A, Ong S, Atar D.** Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. *J Thromb Thrombolysis*. 2008 Apr;25(2):207-13.
- Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallen J, Atar D.** Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. *Cardiology*. 2011;118(3):187-94.
- Shammas NW, Dippel EJ, Lemke JH, Robken J, Kirchner HL, Takes V, Kapalis MJ, Palabrica T.** Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. *J Invasive Cardiol*. 2006 Jan;18(1):6-12.
- Shore-Lesserson L, et al.** Evaluation of the Ultegra[®], point-of-care platelet function instrument during cardiac surgery. *Circulation*. 1999; 99:620-5.
- Siotia A, Buckland R, Judge HM, Sastry P, Storey RF.** Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention. *Thromb Haem*. 2006 Jun;95(6):997-1002.
- Simon DI, Liu CB, Ganz P, Kirshenbaum JM, Piana RN, Rogers C, Selwyn AP, Popma JJ.** A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. *Catheter Cardiovasc Interv*. 2001 Apr;52(4):425-32.
- Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Collier BS.** Rapid platelet-function assay: an automated and quantitative cartridge-based method. *Circulation*. 1999 Feb 9;99(5):620-5.
- Sperling RT, Pinto DS, Ho KK, Carrozza JP Jr.** Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. *Cath Cardiovasc Interv*. 2003 Aug;59(4):459-62.
- Stegnar M.** Platelet function tests and resistance to antiplatelet therapy. Review. *Srp Arh Celok Lek*. 2010 Jan;138 Suppl 1:59-63.
- Steinhubl SR, Talley JD, Braden GA, Tchong JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ.** Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. *Circulation*. 2001 May 29;103(21):2572-8.
- Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Collier BS, Topol EJ, Lincoff AM.** Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. *Circulation*. 1999 Nov9;100(19):1977-82.
- Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators.** Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet*. 2013 Aug 17;382(9892):614-23.
- Storey RF, May JA, Wilcox RG, Heptinstall S.** A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. *Thromb Haemost*. 1999 Oct;82(4):1307-11.
- Van De Graaff E, Steinhubl SR.** Variable Interindividual responses to Antiplatelet Therapies – Do They Exist, Can WE Measure Them, and Are They Clinically Relevant? Insights from the GOLD (AU-Assessing Ultegra) Trial. *Heart Drug* 2001;1:35-43.
- Van Werkum JW, Hackeng CM, de Korte FI, Verheugt FWA, ten Berg JM.** Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. *Neth Heart J*. 2007;15(9):299-305.
- van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM.** The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Review. *Platelets*. 2008 Nov;19(7):479-88.

Voss R, Grebe M, Pralle H, Tillmanns H, Matzdorff A. Pharmacodynamics of two different dosing regimens of tirofiban in citrate or PPACK anticoagulated blood. *Platelets*. 2005 Dec;16(8):492-7.

Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. *Am Heart J*. 2002 Apr;143(4):602-11.

Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PIA2 polymorphism. *Am Heart J*. 2002 Jan;143(1):76-82.

White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPIFA for assessment of platelet function with GPIIB-IIIA antagonists. *J Thromb Thrombolysis*. 2004 Dec;18(3):163-9.

Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. *Thromb Haemost*. 2010 Jan;103(1):29-33.

Wu KK, Willerson JT. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. *Circulation*. 2001 May 29;103(21):2528-30.

Peer-Reviewed Publications Citing the VerifyNow PRUtest / P2Y12 Test

Abtan J, Silvain J, Kerneis M, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Collet JP, Montalescot G. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. *Thromb Haemost.* 2013 Oct 31;110(5):1055-64.

Ahn SG, Yoon J, Kim J, Uh Y, Kim KM, Lee JH, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Tahk SJ, Choe KH. Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting. *Korean Circ J.* 2013 Aug;43(8):541-9.

Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH. Different Prognostic Significance of High On-Treatment Platelet Reactivity as Assessed by the VerifyNow P2Y12 Assay After Coronary Stenting in Patients With and Without Acute Myocardial Infarction. *JACC Cardiovasc Interv.* 2012 Mar; 5 (3):259-67.

Ahn SG, Lee SH, Sung JK, Kim JY, Yoon J. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention. *Platelets.* 2011; 22 (4):305-7.

Alexopoulos D, Xanthopoulou I, Mavronasiou E, Stavrou K, Siapika A, Tsoni E, Davlourous P. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. *Diabetes Care.* 2013 Aug;36(8):2211-6.

Alexopoulos D, Xanthopoulou I, Tsigkas G, Damelou A, Theodoropoulos KC, Makris G, Gizas V, Kassimis G, Davlourous P, Hahalis G. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction. *Thromb Res.* 2013 Apr;131(4):333-7.

Alexopoulos D, Xanthopoulou I, Siapika A, Tsoni E, Stavrou K, Theodoropoulos KC, Davlourous P. Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. *Int J Cardiol.* 2013 Feb 21. doi:10.1016/j.ijcard.2013.01.191.

Alexopoulos D, Xanthopoulou I, Plakomyti TE, Theodoropoulos KC, Mavronasiou E, Damelou A, Hahalis G, Davlourous P. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. *Am Heart J.* 2013 Jan;165(1):73-9.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlourous P, Hahalis G. Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction. *Circ Cardiovasc Interv.* 2012 Dec 1;5(6):797-804.

Alexopoulos D, Xanthopoulou I, Davlourous P, Tsigkas G, Damelou A, Theodoropoulos KC, Gkizas V, Hahalis G. Pre-treatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel and ticagrelor treated patients. *J Thromb Haemost.* 2012 Dec 8. doi:10.1111/jth.12095.

Alexopoulos D. Reloading patients chronically treated with P2Y12 inhibitors and presenting with ACS/PCI: Facing a crossroad? *Int J Cardiol.* 2012 Oct 9. doi:10.1016/j.ijcard.2012.09.202.

Alexopoulos D. Prediction of clopidogrel efficacy and safety: phenotyping and/or genotyping? *Expert Rev Hematol.* 2012;5(4):377-80.

Alexopoulos D, Theodoropoulos KC, Stavrou EF, Xanthopoulou I, Kassimis G, Tsigkas G, Damelou A, Davlourous P, Hahalis G, Athanassiadou A. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. *Cardiovasc Drugs Ther.* 2012 Aug 29. doi:10.1007/s10557-012-6407-z.

Alexopoulos D, Xanthopoulou I, Plakomyti TE, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. *Am J Kidney Dis.* 2012 Aug;60(2):332-3.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. *J Am Coll Cardiol.* 2012 Jul 17;60(3):193-9.

Alexopoulos D, Xanthopoulou I, Tsigkas G, Damelou A, Theodoropoulos KC, Kassimis G, Chouchoulis K, Davlouros P, Chiladakis J, Hahalis G. Predictors of High On-Treatment Platelet Reactivity Early After Clopidogrel Loading in ST-Elevation Myocardial Infarction. *Circ J.* 2012 May 31. doi:10.1253/circj.CJ-12-0173.

Alexopoulos D. Regarding the "Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study". *Am Heart J* 2012;163:e31.

Alexopoulos D. Prasugrel resistance: fact or fiction. *Platelets.* 2012;23(2):83-90.

Alexopoulos D, Plakomyti TE, Xanthopoulou I. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. *Int J Cardiol.* 2012 Feb 9; 154 (3):333-4.

Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, Fourtounas C, Goumenos D. Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. *J Thromb Haemost.* 2011 Dec; 9 (12):2379-85.

Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. *Am Heart J.* 2011 Oct; 162 (4):733-9.

Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. *JACC Cardiovasc Interv.* 2011 Apr; 4 (4):403-10.

Alström U, Granath F, Oldgren J, Ståhle E, Tydén H, Siegbahn A. Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. *Thromb Res.* 2009 Nov; 124 (5):572-7.

Amoah V, Storey RF, Worrall AP, Goodridge K, Lovatt T, Smallwood A, Armesilla AL, Nevill AM, Cotton JM. Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. *Platelets.* 2012 Nov 13. doi:10.3109/09537104.2012.733046.

Amoah V, Worrall AP, Smallwood A, Armesilla AL, Nevill AM, Cotton JM. Clopidogrel and Proton Pump Inhibitors: Can Near Patient Testing Help to Tailor Dual Prescription? *J Thromb Haemost.* 2010 Mar. doi:10.1111/j.1538-7836.2010.03855.x

Ang L, Thani KB, Ilapakurti M, Lee MS, Palakodeti V, Mahmud E. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. *J Am Coll Cardiol.* 2013 Jan 8;61(1):23-34.

Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, Clopton P, Zafar N, Bromberg-Marin G, Keramati S, Mahmud E. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. *J Am Coll Cardiol.* 2008 Sep 23; 52 (13):1052-9.

Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D. Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: Results of the SWAP-2 Study. *J Am Coll Cardiol.* 2013 Dec 11. doi:10.1016/j.jacc.2013.11.032.

Angiolillo DJ, Ferreiro JL, Price MJ, Kirtane AJ, Stone GW. Platelet function and genetic testing. *J Am Coll Cardiol.* 2013 Oct 22;62(17 Suppl):S21-31.

Angiolillo DJ, Rollini F. Switching from prasugrel to clopidogrel: navigating in unknown waters. *JACC Cardiovasc Interv.* 2013 Feb;6(2):166-8.

Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. *J Thromb Thrombolysis.* 2012 May 9. doi:10.1007/s11239-012-0737-3.

Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ, BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. *JAMA.* 2012 Jan 18; 307 (3):265-74.

Angiolillo DJ. Applying platelet function testing in clinical practice: what are the unmet needs? *JAMA.* 2011 Sep 21; 306 (11):1260-1.

Angiolillo DJ, Capranzano P, Ferreira JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Sumner S, Desai B, Charlton RK, Box LC, Zenni M, Guzman LA, Bass TA. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. *Thromb Haemost.* 2011 Aug; 106 (2):253-62.

Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. *Eur Heart J.* 2011 Apr; 32 (7):838-46.

Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB, SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. *J Am Coll Cardiol.* 2010 Sep 21; 56 (13):1017-23.

Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. *Eur Heart J.* 2008 Sep; 29 (18):2202-11.

Angiolillo DJ, Costa MA, Shoemaker SB, Desai B, Bernardo E, Suzuki Y, Charlton RK, Zenni MM, Guzman LA, Bass TA. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. *Am J Cardiol.* 2008 Feb 15; 101 (4):440-5.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. *J Am Coll Cardiol.* 2007 Apr 10; 49 (14):1505-16.

Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. *Eur Heart J.* 2013 Sep 25. doi:10.1093/eurheartj/eh375

Aradi D, Kirtane A, Bonello L, Gurbel PA, et al. Bleeding and Stent Thrombosis on P2Y₁₂-inhibitors: Collaborative Analysis on the Role of Platelet Reactivity for Risk Stratification after Percutaneous Coronary Intervention. *European Heart Journal* 36.27 (2015): 1762-71.

Aradi D, Komócsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, Trenk D, Sibbing D, Valgimigli M, Bonello L; On behalf of the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. *Int J Cardiol.* 2012 Jun 15. doi:10.1016/j.ijcard.2012.05.100.

- Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL.** Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. *Am Heart J.* 2010 Sep; 160 (3):543-51.
- Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y, Berliner S, Deutsch V, Herz I, Keren G, Banai S.** Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. *Clin Cardiol.* 2013 Jun;36(6):342-6.
- Ari H, Ozkan H, Karacinar A, Ari S, Koca V, Bozat T.** The Effect of high-dose Clopidogrel treatment in patients with clopidogrel resistance (The EFFICIENT Trial). *Int J Cardiol.* 2011 Jan 14. doi:10.1016/j.ijcard.2010.12.083
- Azmoon S, Angiolillo DJ.** Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: A Review of the literature and practical considerations for the interventional cardiologist. *Catheter Cardiovasc Interv.* 2012 May 14. doi:10.1002/ccd.24480.
- Babcock MJ, Sane AC, Eckman DM, Sane DC.** Persistent erythema with niacin is not attributable to aspirin resistance. *J Clin Lipidol.* 2011 Mar-Apr; 5 (2):114-9.
- Baber U, Bander J, Karajgikar R, Yadav K, Hadi A, Theodoropoulos K, Gukathasan N, Roy S, Sayeneni S, Scott SA, Kovacic JC, Yu J, Sartori S, Mehran R, Uribarri J, Badimon JJ, Muntner P, Moreno P, Kini AS, Sharma SK.** Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. *Thromb Haemost.* 2013 Jul;110(1):118-23.
- Bagoly Z, Sarkady F, Magyar T, Kappelmayer J, Pongrácz E, Csiba L, Muszbek L.** Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. *PLoS One.* 2013 Jul 2;8(7):e69417. doi:10.1371/journal.pone.0069417.
- Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L.** Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. *Thromb Haemost.* 2010 Sep; 104 (3):571-81.
- Bansal V, Fortlage D, Lee J, Doucet J, Potenza B, Coimbra R.** A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients. *J Trauma.* 2011 Jan; 70 (1):65-9; discussion 69-70.
- Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ.** Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. *JACC Cardiovasc Interv.* 2010 Oct; 3 (10):1001-7.
- Benzon HT, McCarthy RJ, Benzon HA, Kendall MC, Robak S, Lindholm PF, Kallas PG, Katz JA.** Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. *Br J Anaesth.* 2011 Dec; 107 (6):966-71.
- Benzon HT, Fragen R, Benzon HA, Savage J, Robinson J, Puri L.** Clopidogrel and neuraxial block: the role of the PFA II and P2Y12 assays. *Reg Anesth Pain Med.* 2010 Jan-Feb; 35 (1):115.
- Bernlochner I, Morath T, Brown PB, Zhou C, Baker BA, Gupta N, Jakubowski JA, Winters KJ, Schömig A, Kastrati A, Sibbing D.** A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. *Platelets.* 2012 Feb 28. doi:0.3109/09537104.2011.654003.
- Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P.** VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. *Platelets.* 2010; 21 (2):94-100.
- Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M.** Effects of pre-hospital Clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. *J Thromb Haemost.* 2012 Oct 31. doi:10.1111/jth.12049.

Bliden KP, Brener M, Gesheff MG, Franzese CJ, Tabrizchi A, Tantry U, Gurbel PA. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. *Future Cardiol.* 2013 Nov;9(6):785-97.

Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. *Am Heart J.* 2011 Jul; 162(1):160-5.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol.* 2010 Sep 14;56(12):919-33.

Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. *Heart.* 2011 Aug; 97(15):1239-44.

Bouman HJ, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM. A case-control study on platelet reactivity in patients with coronary stent thrombosis. *J Thromb Haemost.* 2011 May; 9(5):909-16.

Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. *J Thromb Haemost.* 2010 Mar; 8(3):482-8.

Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. *J Am Coll Cardiol.* 2011 Nov 1; 58(19):1945-54.

Braun OÖ, Angiolillo DJ, Ferreira JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. *Thromb Haemost.* 2013 Nov 27;110(6):1223-31.

Breet NJ, van Donkersgoed HE, van Werkum JW, Bouman HJ, Kelder JC, Zijlstra F, Hackeng CM, Ten Berg JM. Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. *Neth Heart J.* 2011 Jun; 19(6):279-84.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. *Heart.* 2011 Jun; 97(12):983-90.

Breet NJ, Sluman MA, van Berkel MA, van Werkum JW, Bouman HJ, Harmsze AM, Kelder JC, Zijlstra F, Hackeng CM, Ten Berg JM. Effect of gender difference on platelet reactivity. *Neth Heart J.* 2011 Nov; 19(11):451-7.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. *JAMA.* 2010 Feb 24; 303(8):754-62.

Brizzio ME, Shaw RE, Bosticco B, Collins M, Grau JB, Mak AW, Zapolanski A. Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage. *J Invasive Cardiol.* 2012 Feb; 24(2):49-52.

Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. *Am J Cardiol.* 2007 Jun 1; 99(11):1518-22.

- Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R.** On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. *Thorax*. 2014 Jan;69(1):80-1.
- Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M.** Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. *J Am Coll Cardiol*. 2011 Jun 21; 57 (25):2474-83.
- Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M, 3T/2R Investigators.** Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. *J Am Coll Cardiol*. 2010 Oct 26; 56 (18):1447-55.
- Campo G, Valgimigli M, Carrescia C, Carletti R, Ferrari R.** Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting. *Clin Appl Thromb Hemost*. 2010 Oct; 16 (5):591-3.
- Cannon CP.** Clopidogrel: to test or not to test? That is the question--still. *Clin Chem*. 2011 May; 57 (5):659-61.
- Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Desai B, Tello-Montoliu A, Rollini F, Angiolillo DJ.** Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status. *Catheter Cardiovasc Interv*. 2012 Mar 19. doi:10.1002/ccd.24416.
- Capranzano P, Tamburino C, Capodanno D, Miccichè E, D'Urso L, Calvi V, Angiolillo DJ, Tamburino C.** Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. *Thromb Haemost*. 2011 Nov 30; 106 (6):1149-57.
- Cattaneo M.** The role of laboratory monitoring in antiplatelet therapy. *Handb Exp Pharmacol*. 2012;(210):471-94.
- Cayla G, Cuisset T, Silvain J, O'Connor SA, Kerneis M, Castelli C, Quilici J, Bonnet JL, Alessi MC, Morange PE, Collet JP, Montalescot G.** Prasugrel Monitoring and Bleeding in Real World Patients. *Am J Cardiol*. 2012 Oct 2. doi:10.1016/j.amjcard.2012.08.043.
- Cayla G, Macia JC, Roubille F, Rabesendratana H, Piot C, Schved JF, Leclercq F.** Repeated high doses of clopidogrel in 2 cases of pharmacological resistance. *Circ J*. 2008 Dec; 72 (12):2098-100.
- Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, Park HI, Chang K.** Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. *Biomed Res Int*. 2013;2013:154073. doi:10.1155/2013/154073.
- Chalouhi N, Drueding R, Starke RM, Jabbour P, Dumont AS, Gonzalez LF, Rosenwasser R, Tjoumakaris S.** In-stent stenosis after stent-assisted coiling: incidence, predictors and clinical outcomes of 435 cases. *Neurosurgery*. 2013 Mar;72(3):390-6.
- Chandra RV.** Point of care platelet function testing in routine neurointerventional care is unjustified. *J Neurointerv Surg*. 2013 Jul;5(4):280-2.
- Chen F, Maridakis V, O'neill EA, Beals C, Radziszewski W, de Lepeleire I, Van Dyck K, Depré M, Bolognese JA, de Hoon J, Jacquemin M.** A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel. *Platelets*. 2011 Sep 15. doi:0.3109/09537104.2011.604806
- Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD.** High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. *JACC Cardiovasc Imaging*. 2012 May;5(5):540-9.

- Choi SW, Choi DH, Kim HW, Ku YH, Ha SI, Park G.** Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing. *Platelets*. 2013 Aug 2. doi:10.3109/09537104.2013.821606
- Codner P, Vaduganathan M, Rechavia E, Iakobishvili Z, Greenberg G, Assali A, Hasdai D, Battler A, Kornowski R, Lev EI.** Clopidogrel Response Up to Six Months After Acute Myocardial Infarction. *Am J Cardiol* 2012. doi:10.1016/j.amjcard.2012.03.029
- Cohoon KP, Heit JA.** Should platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes? *Clin Chem*. 2013 Sep;59(9):1299-300.
- Coleman CI, Limone BL.** Universal versus platelet reactivity assay- driven use of P2Y12 inhibitors in acute coronary syndrome patients. Cost-effectiveness analyses for six European perspectives. *Thromb Haemost*. 2013 Oct 17;111(1). doi:10.1160/TH13-07-0557
- Coleman CI, Limone BL.** Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. *Am J Cardiol*. 2013 Aug 1;112(3):355-62.
- Coleman JL, Dahlen JR.** A Unique and Comprehensive Approach to Quality Control. *Point of Care* 2011 Dec; 10(4): 176-178.
- Collet JP, Montalescot G.** Personalized antiplatelet therapy: the wrong approach? *Arch Cardiovasc Dis*. 2013 Oct;106(10):481-6.
- Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, M D EV, Montalescot G; the ARCTIC Investigators.** Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. *N Engl J Med*. 2012 Nov 4.
- Collet JP, van Werkum JW.** Individualised Antiplatelet Therapy – Is There a Role for Platelet Function Testing in Routine Clinical Practice? *European Cardiology*, 2010;6(1):41–9.
- Collet JP, Silvain J, Landivier A, Tanguy ML, Cayla G, Bellemain A, Vignolles N, Gallier S, Beygui F, Pena A, Montalescot G.** Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. *Circulation*. 2008 Sep 16; 118 (12):1225-33.
- Consuegra-Sánchez L, López-Palop R, Cano P, Carrillo P, Picó F, Villegas M, Sanchis J, Kaski JC.** Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease - Concordance between Multiplate and VerifyNow assays. *J Thromb Haemost*. 2013 Feb;11(2):379-81.
- Cotton JM, Worrall AM, Hobson AR, Smallwood A, Amoah V, Dunmore S, Nevill AM, Raghuraman RP, Vickers J, Curzen N.** Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?. *Cardiovasc Ther*. 2010 Jun; 28 (3):139-46.
- Cui YM, Wang ZN, Chen XW, Zhang HL, Zhao X, Zhou Y.** Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects. *Acta Pharmacol Sin*. 2012 Nov;33(11):1395-400.
- Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL.** Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. *Arch Cardiovasc Dis*. 2010 Jan; 103 (1):39-45.
- Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, Barbato E, Bartunek J, De Bruyne B, Wijns W.** Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. *Am J Cardiol*. 2008 Jun 15; 101 (12):1700-3.

Dahlen JR, Price MJ, Parise H, Gurbel PA. Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. *Thromb Haemost.* 2013 May;109(5):808-16.

Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. *Thromb Haemost.* 2013 Oct 24;111(2).

Davlouros P, Mavronasiou E, Damelou A, Xanthopoulou I, Gizas V, Raptis G, Hahalis G, Alexopoulos D. Platelet inhibition by IV glyceryl trinitrate in patients with stable coronary artery disease on dual antiplatelet therapy subjected to PCI. *Int J Cardiol.* 2013 Oct 3;168(3):3069-70.

de Miguel Castro A, Cuellas Ramón C, Diego Nieto A, Samaniego Lampón B, Alonso Rodríguez D, Fernández Vázquez F, Alonso Orcajo N, Carbonell de Blas R, Pascual Vicente C, Pérez de Prado A. Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. *Rev Esp Cardiol.* 2009 Feb; 62 (2):126-35.

Delgado Almandoz JE, Crandall BM, Fease JL, Scholz MJ, Kadkhodayan Y, and Tubman DE. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. *NeurointervSurg* 2014 Jan 7. doi: 10.1136/neurintsurg-2013-010976.

Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, Scholz JM, Fease JL, Tubman DE. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. *J Neurointerv Surg.* 2013 Dec 18. doi:10.1136/neurintsurg-2013-010976.

Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, Tubman DE. Last-Recorded P2Y12 Reaction Units Value Is Strongly Associated with Thromboembolic and Hemorrhagic Complications Occurring Up to 6 Months after Treatment in Patients with Cerebral Aneurysms Treated with the Pipeline Embolization Device. *AJNR Am J Neuroradiol.* 2013 Jul 4. doi:10.3174/ajnr.A3621.

Delgado Almandoz, JE, Crandall, BM, Scholz, JM, Fease, JL, Anderson, RE, Kadkhodayan, Y and Tubman, DE. Last-Recorded P2Y12 Reaction Units Value Is Strongly Associated with Thromboembolic and Hemorrhagic Complications Occurring Up to 6 Months after Treatment in Patients with Cerebral Aneurysms Treated with the Pipeline Embolization Device. *American Journal of Neuroradiology* 35.1 (2013): 128-35.

Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, Tubman DE. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. *J Neurointerv Surg.* 2013 Jan 12. doi:10.1136/neurintsurg-2012-010582

Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A, ARMYDA-5 PRELOAD Investigators. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. *J Am Coll Cardiol.* 2010 Aug 10; 56 (7):550-7.

Diego A, de Prado AP, Cuellas C, de Miguel A, Samaniego B, Alonso-Rodríguez D, Bangueses R, Vega B, Martín J, Fernandez-Vazquez F. P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. *Thromb Res.* 2012 Jun 13. doi:10.1016/j.thromres.2012.05.031.

Diodati JG, Saucedo JF, French JK, Fung AY, Cardillo TE, Hennes C, Efron MB, Fisher HN, Angiolillo DJ. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. *Circ Cardiovasc Interv.* 2013 Oct 1;6(5):567-74. doi:10.1161/CIRCINTERVENTIONS.112.000063.

- Djukanović N, Todorović Z, Njegomirović S, Ostojić M, Prostran M.** Advantages and limitations of clopidogrel response testing methods. *Vojnosanit Pregl.* 2012 Apr;69(4):353-7.
- Drazin D, Choulakian A, Nuño M, Kornbluth P, Alexander MJ.** Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. *J Neurointerv Surg.* 2011 Jun; 3 (2):177-81.
- Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P.** Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y(12) blockade and influence of anticoagulant. *Platelets.* 2011 Aug 17. doi:10.3109/09537104.2011.601361
- Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, Berg JM, Hackeng CM.** The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. *Thromb Haemost.* 2009 Oct; 102 (4):719-27.
- Erlinge D, Gurbel PA, James S, Lindahl TL, Svensson P, Ten Berg JM, Foley DP, Wagner H, Brown PB, Luo J, Zhou C, Moser BA, Jakubowski JA, Small DS, Winters KJ, Angiolillo DJ.** Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. *J Am Coll Cardiol.* 2013 Aug 13;62(7):577-83.
- Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, Zhou C, Luo J, Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ.** Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients: Results From the FEATHER Trial. *J Am Coll Cardiol.* 2012 Nov 13;60(20):2032-40.
- Esposito G.** Responsiveness to P2Y12 receptor inhibitors. *Curr Opin Cardiol.* 2011 Dec; 26 Suppl 1:S31-7.
- Fernando H, Bassler N, Habersberger J, Sheffield LJ, Sharma R, Dart AM, Peter KH, Shaw JA.** Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. *J Thromb Haemost.* 2011 Aug; 9 (8):1582-9.
- Ferreiro JL, Sánchez-Salado JC, Gracida M, Marcano AL, Roura G, Ariza A, Gómez-Lara J, Lorente V, Romaguera R, Homs S, Sánchez-Elvira G, Teruel L, Rivera K, Sosa SG, Gómez-Hospital JA, Angiolillo DJ, Cequier A.** Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation. *J Cardiovasc Transl Res.* 2013 Dec 21.
- Ferreiro JL, Homs S, Berdejo J, Roura G, Gómez-Lara J, Romaguera R, Teruel L, Sánchez-Elvira G, Marcano AL, Gómez-Hospital JA, Angiolillo DJ, Cequier Á.** Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. *Thromb Haemost.* 2013 Jul;110(1):110-7.
- Ferreiro JL, Ueno M, Tello-Montoliu A, Tomasello SD, Seecheran N, Desai B, Rollini F, Guzman LA, Bass TA, Angiolillo DJ.** Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. *JACC Cardiovasc Interv.* 2013 Feb;6(2):182-4.
- Ferreiro JL, Ueno M, Tomasello SD, Capodanno D, Desai B, Dharmashankar K, Seecheran N, Kodali MK, Darlington A, Pham JP, Tello-Montoliu A, Charlton RK, Bass TA, Angiolillo DJ.** Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. *Circ Cardiovasc Interv.* 2011 Jun; 4 (3):273-9.
- Ferreiro JL, Sibbing D, Angiolillo DJ.** Platelet function testing and risk of bleeding complications. *Thromb Haemost.* 2010 Jun; 103 (6):1128-35.
- Ferreiro JL, Ueno M, Capodanno D, Desai B, Dharmashankar K, Darlington A, Charlton RK, Bass TA, Angiolillo DJ.** Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. *Circ Cardiovasc Interv.* 2010 Oct; 3 (5):436-41.

Fifi JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H, Berenstein A, Chong J. Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular Stenting. *AJNR Am J Neuroradiol.* 2012 Nov 29. doi:10.3174/ajnr.A3405.

Fileti L, Campo G, Valgimigli M. Latest clinical data on testing for high on-treatment platelet reactivity. *Rev Cardiovasc Med.* 2011; 12 Suppl 1:S14-22.

Firstenberg MS, Dyke CM, Angiolillo DJ, Ramaiahm C, Price M, Brtko M, Welsby I, Chandna H, Holmes DR, Voeltz M, Tummala P, Hutyra M, Manoukian SV, Prats J, Todd M, Liu T, Chronos N, Dietrich M, Montalescot G, Cannon LA, Topol EJ. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. *Heart Surg Forum.* 2013 Apr;16(2):E60-9.

Fontana P, Cattaneo M, Combescure C, Reny JL. Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping. *J Am Heart Assoc.* 2013 Mar 27;2(2):e000131. doi:10.1161/JAHA.112.000131.

Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. *J Thromb Haemost.* 2006 Apr; 4 (4):813-9.

Fontes-Carvalho R, Albuquerque A, Araújo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. *Eur J Gastroenterol Hepatol.* 2011 May; 23 (5):396-404.

Frelinger AL 3rd, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet Activation and Inhibition in Sickle cell disease (PAINS) study. *Platelets.* 2013 Mar 7. doi:10.3109/09537104.2013.770136.

Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function. *J Am Coll Cardiol.* 2013 Feb 26;61(8):872-9.

Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. *J Am Coll Cardiol.* 2012 Apr 3;59(14):1304-11.

Fujisue K, Sugiyama S, Ono T, Matsuzawa Y, Akiyama E, Sugamura K, Matsubara J, Kurokawa H, Kaikita K, Iwashita S, Sumida H, Hokimoto S, Oniki K, Nakagawa K, Matsui K, Ogawa H. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. *Circ Cardiovasc Interv.* 2013 Aug;6(4):452-9.

Funck-Jensen KL, Dalsgaard J, Grove EL, Hvas AM, Kristensen SD. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. *Platelets.* 2012 Dec 5. doi:10.3109/09537104.2012.738838

Gaglia MA Jr, Torguson R, Pokharel S, Pakala R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity. *Cardiovasc Revasc Med.* 2013 Jan 30. doi:10.1016/j.carrev.2012.12.005.

Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Correlation between Light Transmission Aggregometry, VerifyNow P2Y12, and VASP-P Platelet Reactivity Assays Following Percutaneous Coronary Intervention. *J Interv Cardiol.* 2011 Dec; 24 (6):529-34.

Gaglia MA Jr, Torguson R, Pakala R, Xue Z, Sardi G, Mahmoudi M, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity. *Am J Cardiol.* 2011 Sep 15; 108 (6):766-71.

- Gao LG, Cao J, Mao QX, Lu XC, Zhou XL, Fan L.** Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: A meta-analysis of randomized controlled trials. *Atherosclerosis*. 2012 Nov 2. doi:10.1016/j.atherosclerosis.2012.10.056.
- García-Rinaldi R, Carro-Pagán C, Schaff HV, McKellar SH, Thompson JL 3rd, Quiñones J, Rodríguez-Acosta JF.** Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses. *J Heart Valve Dis*. 2009 Nov; 18 (6):617-25; discussion 626.
- Gasparyan AY.** Aspirin and clopidogrel resistance: methodological challenges and opportunities. *Vasc Health Risk Manag*. 2010;6 109–112.
- Ge J, Zhu J, Hong BK, Boonbaichaiyapruk S, Goh YS, Hou CJ, Pinton P.** Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. *Curr Med Res Opin*. 2010 Sep; 26 (9):2077-85.
- Geara AS, Ayoub I, Abi Rached J, Siddique MN, Ghimire P, El-Sayegh S.** Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test?. *Am J Cardiol*. 2011 Apr 1; 107 (7):1103-4.
- Geisler T, Gawaz M, Steinhubl SR, Bhatt DL, Storey RF, Flather M.** Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. *Pharmacol Ther*. 2010 Aug; 127 (2):95-107.
- Geyik S, Yavuz K, Yurttutan N, Saatci I, Cekirge HS.** Stent-assisted coiling in endovascular treatment of 500 consecutive cerebral aneurysms with long-term follow-up. *AJNR Am J Neuroradiol*. 2013 Nov-Dec;34(11):2157-62.
- Gladding P, White H, Voss J, Ormiston J, Stewart J, Ruygrok P, Bvaldivia B, Baak R, White C, Webster M.** Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. *JACC Cardiovasc Interv*. 2009 Nov; 2 (11):1095-101.
- Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.** The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. *JACC Cardiovasc Interv*. 2008 Dec;1(6):620-7.
- Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.** The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. *JACC Cardiovasc Interv*. 2008 Dec;1(6):612-9.
- Godino C, Mendolicchio L, Figini F, Latib A, Sharp AS, Cosgrave J, Calori G, Cera M, Chieffo A, Castelli A, Maseri A, Ruggeri ZM, Colombo A.** Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel: What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. *Thromb J*. 2009 May 6; 7:4.
- Goh C, Churilov L, Mitchell P, Dowling R, Yan B.** Clopidogrel Hyper-Response and Bleeding Risk in Neurointerventional Procedures. *AJNR Am J Neuroradiol*. 2012 Dec 28. doi:10.3174/ajnr.A3418.
- Gorog DA, Fuster V.** Platelet function tests in clinical cardiology: unfulfilled expectations. *J Am Coll Cardiol*. 2013 May 28;61(21):2115-29.
- Goto S, Tomiya A.** High on-treatment platelet reactivity (HPR): What does it mean, and does it matter? *Thromb Haemost*. 2013 Jan 31;109(2):177-8.
- Gray BH.** Platelet inhibitors: balancing art and science. *Endovasc Today*. 2012 July;11(7):29-32.

- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. *Thromb Haemost.* 2013 Nov 7;111(3). doi:10.1160/TH13-07-0558.
- Gremmel T, Müller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, Panzer S.** Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. *Nephrol Dial Transplant.* 2013 Aug;28(8):2116-22.
- Gremmel T, Panzer S, Steiner S, Seidinger D, Koppensteiner R, Pabinger I, Kopp CW, Ay C.** Response to antiplatelet therapy is independent of endogenous thrombin generation potential. *Thromb Res.* 2013 Jul;132(1):e24-30.
- Gremmel T, Kopp CW, Moertl D, Seidinger D, Koppensteiner R, Panzer S, Mannhalter C, Steiner S.** Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. *Thromb Res.* 2012 May;129(5):616-22.
- Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Panzer S, Sunder-Plassmann R, Mannhalter C, Steiner S.** Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. *Int J Cardiol.* 2011 Nov 8. doi:10.1016/j.ijcard.2011.10.010.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. *Thromb Res.* 2011 Oct; 128 (4):352-7.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. *Int J Cardiol.* 2011 May 3. doi:10.1016/j.ijcard.2011.04.001.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. *J Cardiovasc Pharmacol.* 2010 Nov; 56 (5):532-9.
- Gremmel T, Kopp CW, Seidinger D, Giurgea GA, Koppensteiner R, Steiner S, Panzer S.** The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. *Atherosclerosis.* 2009 Dec; 207 (2):608-13.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. *Thromb Res.* 2009 Nov; 124 (5):588-91.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. *Thromb Haemost.* 2009 Feb; 101 (2):333-9.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. *Heart.* 2010 Feb; 96 (3):186-9.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.** Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. *J Thromb Haemost.* 2010 Jan; 8 (1):37-42.
- Gurbel PA, Tantry US.** The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. *Intervent Cardiol Clin.* 2013. doi:10.1016/j.iccl.2013.05.009.
- Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA.** The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. *J Am Coll Cardiol.* 2013 Aug 6;62(6):505-12.

Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KA, Prabhakaran D, Armstrong PW, Tantry US, Roe MT; for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy. *JAMA*. 2012 Nov 4:1-10.

Gurbel PA, Tantry US. Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. *Circulation*. 2012 Mar 13; 125 (10):1276-87.

Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. *JAMA*. 2011 Mar 16;305(11):1136-7.

Gurbel PA, Mahla E, Tantry US. Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. *Thromb Haemost*. 2011 Aug;106(2):248-52.

Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. *J Am Coll Cardiol*. 2010 Jul 6;56(2):112-6.

Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. *Circulation*. 2010 Mar 16; 121 (10):1188-99.

Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. *J Thromb Haemost*. 2010 Jan; 8 (1):43-53.

Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. *Circulation*. 2009 Dec 22; 120 (25):2577-85.

Gurbel PA, Tantry US. Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. *Curr Treat Options Cardiovasc Med*. 2009 Feb;11(1):22-32.

Gurbel PA, Tantry US. Clopidogrel resistance? *Thromb Res*. 2007;120(3):311-21.

Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol*. 2007 Nov 6;50(19):1822-34.

Ha SJ, Kim SJ, Hwang SJ, Woo JS, Kim W, Kim WS, Kim KS, Kim MK. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. *Coron Artery Dis*. 2013 Dec;24(8):690-7.

Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, Barbato E. Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. *J Thromb Thrombolysis*. 2011 Jul; 32 (1):64-71.

Haraguchi K, Miyachi S, Izumi T, Matsubara N, Naito T, Asai T, Yamanouchi T, Wakabayashi T. Resistance to Antiplatelet Agents Assessed by a Point-of-care Platelet Function Test and Thromboembolic Adverse Events in Neurointervention. *No Shinkei Geka*. 2012 May;40(5):399-406.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. *Pharmacogenet Genomics*. 2010 Jan; 20 (1):18-25.

- Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, ten Berg JM, Klungel OH, de Boer A, Deneer VH.** Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. *J Thromb Haemost.* 2011 Oct; 9 (10):1892-901.
- Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, Ruven HJ, Klungel OH, de Boer A, Deneer VH.** The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. *Thromb Haemost.* 2010 May; 103 (5):920-5.
- Harrison P.** Advances in the monitoring of anti-P2Y12 therapy. *Platelets* 2012 Aug 23. doi:10.3109/09537104.2012.704650.
- Hobson AR, Qureshi Z, Banks P, Curzen N.** The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses. *Thrombosis.* 2010; 2010:908272.
- Hobson AR, Petley G, Morton G, Dawkins KD, Curzen NP.** Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. *Thromb J.* 2008 Feb 29; 6:1.
- Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M.** Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. *Clin Pharmacol Ther.* 2013 Sep 25. doi:10.1038/clpt.2013.192.
- Holmberg MT, Tornio A, Joutsu-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, Niemi M, Backman JT.** Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. *Br J Clin Pharmacol.* 2013 Jun;75(6):1488-96.
- Htun P, Kan T, Mueller E, Pohle C, Schindler R, Geisler T, Gawaz M, Bocksch W, Fateh-Moghadam S.** Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end stage renal disease. Results of a pilot study. *Thromb Haemost.* 2013 Dec 12;111(4). doi: 10.1160/TH13-04-0289.
- Hu YF, Lu TM, Wu CH, Lin YJ, Chang SL, Lo LW, Tuan TC, Chao TF, Chung FP, Liao JN, Tzeng CH, Chen SA, Tsao HM.** Differences in high on-treatment platelet reactivity between intra-coronary and peripheral blood after dual anti-platelet agents in patients with coronary artery disease. *Thromb Haemost.* 2013 Jul;110(1):124-30.
- Huczek Z, Filipiak KJ, Kochman J, Michalak M, Roik M, Grabowski M, Opolski G.** Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. *Platelets.* 2011; 22 (7):521-9.
- Huczek Z, Filipiak KJ, Kochman J, Michalak M, Roik M, Piatkowski R, Grabowski M, Postula M, Opolski G.** Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity A case-control study. *Thromb Res.* 2010 May; 125 (5):406-12.
- Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY.** The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. *Thromb Res.* 2011 Jan; 127 (1):23-8.
- Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S.** Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv.* 2010 Oct; 3 (5):450-9.
- Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL 3rd, Howard J, Mant TG, Jurcevic S, Payne CD.** A Phase 1 Study of Prasugrel in Patients with Sickle Cell Disease: Pharmacokinetics and Effects on ex Vivo Platelet Reactivity. *Br J Clin Pharmacol.* 2012 Nov 21. doi:10.1111/bcp.12042.
- Jakubowski JA, Zhou C, Egan B, Wells M, Kotob-Yahfoufi M, Sugidachi A, Dahlen JR.** Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism. *Platelets.* 2011; 22 (8):619-25.

- Jakubowski JA.** Beyond platelet functional testing: value in the aggregate. *Biomark Med.* 2011 Feb;5(1):5-8.
- Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Luo J, Winters KJ.** A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. *J Cardiovasc Pharmacol.* 2010 Jul; 56 (1):29-37.
- Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.** The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. *Thromb Haemost.* 2008 Feb; 99 (2):409-15.
- Jang J, Lim J, Chang K, Kim Y, Kim M, Il Park H, Kim J, Shin S.** A Comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. *J Clin Lab Anal.* 2012 Jul;26(4):262-6. doi:10.1002/jcla.21515.
- Janssen PW, ten Berg JM.** Platelet function testing and tailored antiplatelet therapy. *J Cardiovasc Transl Res.* 2013 Jun;6(3):316-28.
- Jeong YH, Tantry US, Min JH, Park Y, Navarese EP, Koh JS, Park JR, Hwang SJ, Kho EH, Bliden KP, Kwak CH, Hwang JY, Kim S, Gurbel PA.** Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. *Int J Cardiol.* 2012 Oct 12. doi:10.1016/j.ijcard.2012.09.132.
- Jeong YH, Tantry US, Park Y, Kwon TJ, Park JR, Hwang SJ, Bliden KP, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA.** Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention. *Diabetes Care.* 2012 Jul 26. doi:10.2337/dc11-2351.
- Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA.** Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. *Am Heart J.* 2012 Jul;164(1):35-42.
- Jeong YH, Park Y, Muse WC, Kwon TJ, Koh JS, Hwang SJ, Kwak CH, Hwang JY.** Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study. *J Thromb Haemost.* 2012 May 22. doi:10.1111/j.1538-7836.2012.04788.x.
- Jeong YH, Bliden KP, Antonino MJ, Tantry US, Gurbel PA.** Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. *Platelets.* 2012 May 30. doi:10.3109/09537104.2012.675108.
- Jeong YH, Bliden KP, Tantry US, Gurbel PA.** High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? *J Thromb Haemost.* 2012 Mar;10(3):487-9. doi:10.1111/j.1538-7836.2011.04604.x.
- Jeong YH, Park Y, Bliden KP, Tantry US, Gurbel PA.** High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. *Heart.* 2012 Feb;98(4):343.
- Jeong YH, Bliden KP, Tantry US, Gurbel PA.** The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. *J Am Coll Cardiol.* 2011 Dec 13;58(25):2701-2.
- Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA.** Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin. *Circ Cardiovasc Interv.* 2011 Dec 1; 4 (6):585-94.
- Jeong YH, Tantry US, Bliden KP, Gurbel PA.** Cilostazol to overcome high on-treatment platelet reactivity in Korean patients treated with clopidogrel and calcium-channel blocker. *Circ J.* 2011;75(11):2534-6.

- Jeong YH, Cho JH, Kang MK, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY.** Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. *Thromb Res.* 2010 Oct; 126 (4):e334-8.
- Jeong YH, Kim IS, Park Y, Kang MK, Koh JS, Hwang SJ, Kwak CH, Hwang JY.** Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. *JACC Cardiovasc Interv.* 2010 Jul; 3 (7):731-41.
- Jeong YH, Koh JS, Kang MK, Ahn YJ, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY.** The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. *Korean J Intern Med.* 2010 Jun; 25 (2):154-61.
- Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW.** Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. *Circ Cardiovasc Interv.* 2010 Feb 1; 3 (1):17-26.
- Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW.** Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. *J Am Coll Cardiol.* 2009 Mar 31; 53 (13):1101-9.
- Jeong YH, Kim IS, Choi BR, Kwak CH, Hwang JY.** The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. *Eur Heart J.* 2008 Sep; 29 (17):2186-7; author reply 2187.
- Jin EZ, Yu LH, Li XQ.** Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention. *Int Heart J.* 2012;53(1):1-4.
- Jin HY, Yang TH, Kim DI, Chung SR, Seo JS, Jang JS, Kim DK, Kim DK, Kim KH, Seol SH, Nam CW, Hur SH, Kim W, Park JS, Kim YJ, Kim DS.** High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. *Int J Cardiol.* 2012 Jun 9. doi:10.1016/j.ijcard.2012.04.154.
- Jung HJ, Sir JJ.** Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance. *J Invasive Cardiol.* 2011 Feb; 23 (2):E15-8.
- Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, Nakamura S, Tsujita K, Tayama S, Hokimoto S, Sakamoto T, Nakao K, Oshima S, Sugiyama S, Ogawa H.** Impact of CYP2C19 Polymorphism on Platelet Function Tests and Coagulation and Inflammatory Biomarkers in Patients Undergoing Percutaneous Coronary Intervention. *J Atheroscler Thromb.* 2013 Oct 1. doi:
- Kakouros N, Kickler TS, Laws KM, Rade JJ.** Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. *J Thromb Haemost.* 2013 Oct;11(10):1814-22.
- Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepis AD.** The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. *Platelets.* 2012;23(2):121-31.
- Kanemaru K, Nishiyama Y, Yoshioka H, Satoh K, Hashimoto K, Hanihara M, Horikoshi T, Ozaki Y, Kinouchi H.** In-stent thrombosis after carotid artery stenting despite sufficient antiplatelet therapy in a bladder cancer patient. *J Stroke Cerebrovasc Dis.* 2013 Oct;22(7):1196-200.
- Kang DY, Yang HM, Park KW, Lee SR, Lee MH, Lee DW, Lee HY, Kang HJ, Koo BK, Chae IH, Choi DJ, Kim HS, Kim CH.** Lack of association between low density lipoprotein particle size and on-treatment platelet reactivity in patients with coronary artery disease. *Korean Circ J.* 2012 Aug;42(8):551-7.

- Kang HS, Kwon BJ, Kim JE, Han MH.** Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. *AJNR Am J Neuroradiol.* 2010 Aug; 31 (7):1206-10.
- Kang MK, Jeong YH, Yoon SE, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY.** Pre-procedural platelet reactivity after clopidogrel loading in Korean patients undergoing scheduled percutaneous coronary intervention. *J Atheroscler Thromb.* 2010 Nov 27; 17 (11):1122-31.
- Karon BS, Montalescot G, Harris NS, Kristensen SR, Price M.** Novel Uses for Platelet Function Testing in the Clinical Laboratory: Where Are We Now? *Clin Chem.* 2013 Oct 2. doi:10.1373/clinchem.2013.208942.
- Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D.** CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. *Thromb Res.* 2012 Apr;129(4):441-6.
- Kehrel BE, Brodde MF.** State of the art in platelet function testing. *Transfus Med Hemother.* 2013 Apr;40(2):73-86.
- Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignatou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.** Switching acute coronary syndrome patients from prasugrel to clopidogrel. *JACC Cardiovasc Interv.* 2013 Feb;6(2):158-65.
- Kidson-Gerber G, Weaver J, Gemmell R, Prasan AM, Chong BH.** Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. *Heart Lung Circ.* 2010 Apr; 19 (4):234-42.
- Kim BJ, Lee SW, Park SW, Kang DW, Kim JS, Kwon SU.** Insufficient Platelet Inhibition Is Related to Silent Embolic Cerebral Infarctions After Coronary Angiography. *Stroke.* 2011 Dec 29. doi:10.1161/STROKEAHA.111.641340.
- Kim BK, Oh SJ, Yoon SJ, Jeon DW, Ko YG, Yang JY.** A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. *Yonsei Med J.* 2011 Sep; 52 (5):717-26.
- Kim H, Lee HK, Han K, Jeon HK.** Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. *Ann Clin Lab Sci.* 2009 Summer; 39 (3):289-94.
- Kim HS, Cho DY, Park BM, Bae SK, Yoon YJ, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG.** The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. *J Clin Pharmacol.* 2013 Nov 11. doi:10.1002/jcph.225.
- Kim IS, Jeong YH, Park Y, Yoon SE, Kwon TJ, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.** Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: Results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. *Br J Clin Pharmacol.* 2011 Oct 19. doi:10.1111/1365-2125.2011.04131.x.
- Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.** Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. *JACC Cardiovasc Interv.* 2011 Apr; 4 (4):381-91.
- Kim IS, Jeong YH, Kang MK, Koh JS, Park Y, Hwang SJ, Kwak CH, Hwang JY, Kim S.** Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. *J Thromb Thrombolysis.* 2010 Nov; 30 (4):486-95.
- Kim IS, Choi BR, Jeong YH, Kwak CH, Kim S.** The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. *J Thromb Haemost.* 2009 May; 7 (5):897-9.
- Kim MH, Zhang HZ, Jung DK.** Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers. *Circ J.* 2013;77(5):1253-9.

- Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH.** Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. *Circ J.* 2007 Dec; 71 (12):1867-72.
- Kinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O'Neill D, Murphy RP, McCabe DJ.** Prevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100® and VerifyNow®. *J Stroke Cerebrovasc Dis.* 2012 Sep 12. doi:10.1016/j.jstrokecerebrovasdis.2012.07.012.
- Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, Hong MK, Seo MK, Youn TJ, Chae IH, Choi DJ, Jang Y.** Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. *Am Heart J.* 2011 Feb; 161 (2):383-90.
- Kounis NG, Grapsas N.** Pathways of platelet activation and unexplained clopidogrel variability: causes of poor response to clopidogrel. *Thromb Res.* 2013 Aug;132(2):312.
- Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, Breall JA, Li L, Chiang C, Kovacs R, Flockhart DA, Jin Y.** Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. *Clin Pharmacol.* 2012;4:13-20.
- Krishna V, Diamond GA, Kaul S.** The role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. *Circulation.* 2012 Mar 13;125(10):1288-303.
- Laine M, Frere C, Ronsin O, Gaubert M, Toesca R, Bessereau J, Michelet P, Gramond C, Helal O, Paganelli F, Bonello L.** Assessing post-treatment platelet reactivity: a focus on patient selection and setting. *Expert Rev Cardiovasc Ther.* 2013 Nov;11(11):1557-66.
- Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.** Impact of initial clinical presentation on clopidogrel low response. *Arch Cardiovasc Dis.* 2013 Nov;106(11):593-600.
- Leadbeater PD, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, Mitchell JA, Warner TD.** Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. *J Thromb Haemost.* 2011 Oct; 9 (10):2050-6.
- Lee DH, Kim MH, Park TH, Park JS, Park K, Zhang HZ, Seo JM, Lee MS.** Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial. *Trials.* 2013 Feb 28;14(1):62. doi:10.1186/1745-6215-14-62
- Lee DH, Kim HS, Kim SM, Kwon SU, Suh DC.** Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting. *Neurointervention.* 2012 Feb;7(1):23-6.
- Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME.** Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. *Am J Neuroradiol.* 2008 Aug; 29 (7):1389-94.
- Lee GY, Hahn JY, Lee SY, Kim HJ, Kim JH, Lee SY, Song YB, Choi SH, Choi JH, Gwon HC.** Adjunctive Cilostazol versus High Maintenance Dose of Clopidogrel in Patients with Hyporesponsiveness to Chronic Clopidogrel Therapy. *Yonsei Med J.* 2013 Jan 1;54(1):34-40. doi:10.3349/yjmj.2013.54.1.34.
- Lee JB, Lee KA, Lee KY.** Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease. *Yonsei Med J.* 2011 Sep; 52 (5):734-8.
- Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, Kim JS, Shin ES, Chang CW, Lee JE, Jang Y.** Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. *Am J Cardiol.* 2009 Jul 1; 104 (1):46-51.
- Lee K, Kim JY, Yoo BS, Yoon J, Hong MK, Ahn MS, Choe H, Lee SH.** Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. *J Thromb Haemost.* 2010 Nov;8(11):2577-9.

Lee K, Lee SW, Lee JW, Kim SY, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH. The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p2y12 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. *Korean Circ J.* 2009 Dec; 39 (12):512-8.

Lee SP, Bae JW, Park KW, Rha SW, Bae JH, Suh JW, Chae IH, Cho MC, Kim HS. Inhibitory interaction between calcium channel blocker and clopidogrel -Efficacy of cilostazol to overcome it-. *Circ J.* 2011 Oct 25; 75 (11):2581-9.

Lee SP, Park KW, Shin DH, Lee HY, Kang HJ, Koo BK, Suh JW, Youn TJ, Choi DJ, Chae IH, Kim HS. Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy. *J Atheroscler Thromb.* 2011; 18 (10):914-23.

Lee SP, Suh JW, Park KW, Lee HY, Kang HJ, Koo BK, Chae IH, Choi DJ, Rha SW, Bae JW, Cho MC, Kwon TG, Bae JH, Kim HS, CILON-T investigators. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. *Trials.* 2010 Aug 24; 11:87.

Lemesle G, Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM. Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. *Platelets.* 2013 Oct 31. doi:10.3109/09537104.2013.840363.

Leng WX, Ren JW, Cao J, Cong YL, Cui H, Hu GL, Hu QQ, Niu H, Fan L. Chronic kidney disease - Is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease? *Thromb Res.* 2013 Jan 19. doi:10.1016/j.thromres.2013.01.008.

Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. *J Thromb Thrombolysis.* 2013 Jul 14. doi:10.1007/s11239-013-0966-0.

Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Interventions: The ACHIDO (Atorvastatin and Clopidogrel High DOse in stable patients with residual high platelet activity) Study. *JACC Cardiovasc Interv.* 2013 Feb;6(2):169-79.

Leslie-Mazwi TM. Antiplatelet testing in neurointervention: we cannot ignore the signs. *J Neurointerv Surg.* 2013 Jul;5(4):277-9.

Lhermusier T, Voisin S, Mejean S, Garcia C, Sié P, Carrié D. Switching patients from clopidogrel to prasugrel in acute coronary syndrome. Effects of prasugrel loading dose on residual platelet reactivity. *J Thromb Haemost.* 2012 Jul 2. doi:10.1111/j.1538-7836.2012.04838.x.

Li AY, Ng FH, Chan FK, Tunggal P, Chan K, Lau YK. Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial. *Heart* 2012 Oct 31. doi:10.1136/heartjnl-2012-302801.

Li J, Jian Z, Song M, Guo W, Chen G, Lu W, Qian D, Ouyang J, Yu J, Hu H, Jin J, Wu X, Huang L. Tailored antiplatelet therapy and clinical adverse outcomes. *Heart.* 2014 Jan;100(1):41-6.

Lin PC, Jones SO, McGlasson DL. Effects of glucosamine and Celadrin on platelet function. *Clin Lab Sci.* 2010 Winter; 23 (1):32-6.

Lopez-Alonso A, Jose B, Somers M, Egan K, Foley DP, Ricco AJ, Ramström S, Basabe-Desmonts L, Kenny D. Individual platelet adhesion assay: measuring platelet function and antiplatelet therapies in whole blood via digital quantification of cell adhesion. *Anal Chem.* 2013 Jul 2;85(13):6497-504.

Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease. *Am J Cardiol.* 2009 Nov 1; 104 (9):1189-93.

Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. *Eur Heart J.* 2008 Dec; 29 (23):2877-85.

Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Diodati JG. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. *Ther Drug Monit.* 2008 Jun; 30 (3):372-8.

Luchessi AD, Silbiger VN, Hirata RD, Lima-Neto LG, Cavichioli D, Iñiguez A, Bravo M, Bastos G, Sousa AG, Brión M, Carracedo A, Hirata MH. Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients. *Clin Chim Acta.* 2013 Oct 21;425:9-17.

Luchessi AD, Silbiger VN, Cerda A, Hirata RD, Carracedo A, Brion M, Iñiguez A, Bravo M, Bastos G, Sousa AG, Hirata MH. Increased clopidogrel response is associated with ABCC3 expression: A pilot study. *Clin Chim Acta.* 2012 Feb 18; 413 (3-4):417-21.

Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. *Clin Chem.* 2010 May; 56 (5):839-47.

Mahmud E, Ang L. Platelet function testing in practice: a case study. *Rev Cardiovasc Med.* 2011; 12 Suppl 1:S34-9.

Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. *Thromb Res.* 2007; 119 (3):277-84.

Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. *Methods Find Exp Clin Pharmacol.* 2006 Jun; 28 (5):315-22.

Mallouk N, Labruyère C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S. Prevalence of poor biological response to clopidogrel: a systematic review. *Thromb Haemost.* 2012 Mar;107(3):494-506.

Mangiapra F, Peace A, Barbato E, Patti G, Gatto L, Ricottini E, De Bruyne B, Di Sciacio G, Wijns W. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. *Platelets.* 2013 Aug 23. doi:10.3109/09537104.2013.824562.

Mangiapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciacio G. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. *JACC Cardiovasc Interv.* 2012 Mar;5(3):281-9.

Mangiapra F, Peace AJ, Wijns W, Barbato E. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. *J Thromb Thrombolysis.* 2011 Jul; 32 (1):54-8.

Mangiapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, Barbato E, Di Sciacio G. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. *Am J Cardiol.* 2010 Sep 1; 106 (5):619-23.

Mangiapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciacio G. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2010 Mar; 3 (3):318-23.

Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato E. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2010 Jan; 3 (1):35-40.

Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. *Heart.* 2012 Dec;98(23):1710-5.

Marcucci R, Gori AM, Panicia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antonucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. *Circulation.* 2009 Jan 20; 119 (2):237-42.

Maruyama H, Fukuoka T, Deguchi I, Ohe Y, Nagoya H, Kato Y, Horiuchi Y, Hayashi T, Tanahashi N. Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke. *Intern Med.* 2013;52(10):1043-7.

Maruyama H, Takeda H, Dembo T, Nagoya H, Kato Y, Fukuoka T, Deguchi I, Horiuchi Y, Tanahashi N. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. *Intern Med.* 2011; 50 (7):695-8.

Matsubara Y. Low Responsiveness to Antiplatelet Drugs. *J Jpn Coll Angiol.* 2011, 51: 309–314.

McGlasson DL, Shah AD, Fritsma GA. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangioplasty individuals. *Blood Coagul Fibrinolysis.* 2011 Oct; 22 (7):583-7.

McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. *Crit Pathw Cardiol.* 2006 Jun; 5 (2):103-13.

McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. *Future Cardiol.* 2006 May; 2 (3):255-67.

Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. *JAMA.* 2011 Nov 23; 306 (20):2221-8.

Michalak M, Huczek Z, Filipiak KJ, Roik MF, Kochman J, Opolski G. Periprocedural myocardial damage during percutaneous coronary intervention: a point-of-care platelet testing and intravascular ultrasound/virtual histology study. *Kardiol Pol.* 2013;71(4):325-33.

Michelson AD. Methods for the Measurement of Platelet Function. *Am J Cardiol.* 2009;103[suppl]:20A–26A.

Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM. Clinical consequences of aspirin and clopidogrel resistance: an overview. *Acta Neurol Scand.* 2013 Oct;128(4):213-9.

Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. *Thromb Res.* 2011 Nov; 128 (5):458-62.

Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome The randomised, double-blind ACAPULCO study. *Thromb Haemost.* 2010 Jan; 103 (1):213-23.

Morris A, Aliprandi-Costa B, Brieger D. Platelet function analysis: a comparison of methods. *Int J Cardiol.* 2010 Nov 5; 145 (1):167-8.

- Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, Hannedouche T, Gachet C, Moulin B, Morel O.** Association of Estimated GFR With Platelet Inhibition in Patients Treated With Clopidogrel. *Am J Kidney Dis.* 2012 Mar 14. doi:10.1053/j.ajkd.2011.12.027
- Muller O, Hamilos M, Bartunek J, Ulrichs H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruyse K, De Bruyne B, Wijns W, Barbato E.** Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol.* 2010 Feb 1; 105 (3):333-8.
- Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K.** Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. *J Cardiol.* 2013 Sep;62(3):158-64.
- Nakagawa I, Wada T, Park HS, Nishimura F, Yamada S, Nakagawa H, Kichikawa K, Nakase H.** Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. *J Vasc Surg.* 2013 Nov 14. doi:10.1016/j.jvs.2013.09.011.
- Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, Hoshino K, Aoki T, Nishimura Y, Tamaru S, Ito M, Nishikawa M; McLordd Group.** Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. *Circ J.* 2013;77(6):1436-44.
- Nasyuhana Sani Y, Sheau Chin L, Luen Hui L, Mohd Redhuan Shah Edwin NE, Teck Hwa G, Serebruany VL, Kah Hay Y.** The CYP2C19(*)1/(*)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. *Cardiol Res Pract.* 2013;2013:128795. doi:10.1155/2013/128795.
- Nishio R, Shinke T, Otake H, Nakagawa M, Inoue T, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Kuroda M, Hirata K.** Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers. *Thromb Res.* 2013 Nov;132(5):558-64.
- Nishio R, Shinke T, Otake H, Shite J, Hirata K.** Influence of rabeprazol on the incidence of intra-stent thrombus after drug-eluting stent implantation in Japanese CYP2C19 loss-of-function carriers. *J New Rem Clin.* 2012; 61(4):56-64.
- Nordeen JD, Patel AV, Darracott RM, Johns GS, Tausky P, Tawk RG, Miller DA, Freeman WD, Hanel RA.** Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications. *J Vasc Interv Neurol.* 2013 Jun;6(1):26-34.
- Nührenberg TG, Trenk D, Leggewie S, Ristau I, Amann M, Stratz C, Hochholzer W, Valina CM, Neumann FJ.** Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. *Platelets.* 2012 Dec 5. doi:10.3109/09537104.2012.736045.
- Nusca A, Patti G, Di Sciascio G.** Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. *J Cardiovasc Transl Res.* 2013 Jan 3. doi:10.1007/s12265-012-9439-7.
- Oestreich JH, Steinhubl SR, Ferraris SP, Akers WS.** High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. *Thromb Haemost.* 2011 May;105(5):927-30.
- Oestreich JH, Holt J, Dunn SP, Smyth SS, Campbell CL, Charnigo R, Akers WS, Steinhubl SR.** Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. *Coron Artery Dis.* 2009 May; 20 (3):207-13.
- Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS.** Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. *Heart.* 2012 Jan; 98 (2):139-44.

Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. *Thromb Res.* 2011 Dec; 128 (6):e130-6.

Osmancik P, Paulu P, Tousek P, Kocka V, Widimsky P. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. *J Thromb Thrombolysis.* 2011 Dec 22. Doi: 10.1007/s11239-011-0659-5

Palmerini T, Barozzi C, Tomasi L, Sangiorgi D, Marzocchi A, De Servi S, Ortolani P, Reggiani LB, Alessi L, Lauria G, Bassi M, Branzi A. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. *Thromb Res.* 2010 Apr; 125 (4):309-14.

Panchal HB, Shah T, Patel P, Albalbissi K, Molnar J, Coffey B, Khosla S, Ramu V. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis. *J Cardiovasc Pharmacol Ther.* 2013 Nov;18(6):533-43.

Paniccia R, Antonucci E, Maggini N, Miranda M, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study. *Ther Drug Monit.* 2011 Feb; 33 (1):94-8.

Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. *Thromb Haemost.* 2010 Aug; 104 (2):287-92.

Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antonucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. *J Thromb Haemost.* 2007 Sep; 5 (9):1839-47.

Park DW, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Yun SC, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. *Am Heart J.* 2013 Jan;165(1):34-42.e1.

Park DW, Lee SW, Yun SC, Song HG, Ahn JM, Lee JY, Kim WJ, Kang SJ, Kim YH, Lee CW, Park SW, Park SJ. A Point-of-Care Platelet Function Assay and C-Reactive Protein for Prediction of Major Cardiovascular Events After Drug-Eluting Stent Implantation. *J Am Coll Cardiol.* 2011 Dec 13; 58 (25):2630-9.

Park J, Shin DH, Kim BK, Her AY, Kim YH, Choi HH, Kim JS, Ko YG, Choi D, Jang Y, Hong MK. Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation. *Eur Heart J Cardiovasc Imaging.* 2013 Dec;14(12):1181-6.

Park JB, Koo BK, Choi WG, Kim SY, Park J, Kwan J, Park CG, Kim HS. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. *Clin Ther.* 2013 Jan;35(1):28-37.e4.

Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. *Int J Cardiol.* 2013 Feb 10;163(1):79-86. doi:10.1016/j.ijcard.2012.09.075.

Park JJ, Woo Park K, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. CYP3A4 Genetic Status May Be Associated With Increased Vulnerability to the Inhibitory Effect of Calcium-Channel Blockers on Clopidogrel. *Circ J.* 2013 Feb 9. doi:10.1253/circj.CJ-12-0682.

Park KH, Jeong MH, Lee KH, Sim DS, Yoon HJ, Yoon NS, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction. *J Cardiol.* 2013 Sep 5. doi:10.1016/j.jcc.2013.07.004.

Park KJ, Chung HS, Kim SR, Kim HJ, Han JY, Lee SY. Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. *Korean J Lab Med.* 2011 Apr; 31 (2):91-4.

Park KW, Park JJ, Kang J, Jeon KH, Kang SH, Han JK, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability but Is Associated with Clinical Outcome after PCI. *PLoS One.* 2013;8(2):e52779. doi:10.1371/journal.pone.0052779.

Park KW, Kim HS. Options to Overcome Clopidogrel Response Variability. *Circ J.* 2012;76(2):287-92.

Park KW, Kang SH, Kang J, Jeon KH, Park JJ, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. *Heart.* 2012 May 9. doi:10.1136/heartjnl-2011-301565.

Park KW, Jeon KH, Kang SH, Oh IY, Cho HJ, Lee HY, Kang HJ, Park SK, Koo BK, Oh BH, Park YB, Kim HS. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). *Am J Cardiol.* 2011 Dec 1; 108 (11):1556-63.

Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. *Heart.* 2011 Apr; 97 (8):641-7.

Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Clinical Predictors of High Posttreatment Platelet Reactivity to Clopidogrel in Koreans. *Cardiovasc Ther.* 2010 Dec 6. doi:10.1111/j.1755-5922.2010.00249.x.

Park MW, Her SH, Kim HS, Choi YS, Park CS, Koh YS, Park HJ, Kim PJ, Kim CJ, Jeon DS, Shin DI, Seo SM, Yoo KD, Kim DB, Kim HY, Lee JM, Chung WS, Seung KB, Shin JG, Chang K. Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. *Pharmacogenet Genomics.* 2013 Oct;23(10):558-62.

Park SH, Kim YB, Huh SK. Effect of premedication method and drug resistance of antiplatelet agent on periprocedural thromboembolic events during coil embolization of an unruptured intracranial aneurysm. *J Cerebrovasc Endovasc Neurosurg.* 2012 Sep;14(3):148-56.

Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. *Am J Cardiol.* 2009 Nov 1; 104 (9):1292-5.

Park SJ, Oh IY, Kim KH, Shin DH, Yang HM, Lee HY, Koo BK. Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. *Int J Cardiol.* 2011 Jun 2; 149 (2):e85-7.

Park Y, Jeong YH, Tantry US, Ahn JH, Kwon TJ, Park JR, Hwang SJ, Gho EH, Bliden KP, Kwak CH, Hwang JY, Kim S, Gurbel PA. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. *Eur Heart J.* 2012 Apr 16. doi:10.1093/eurheartj/ehs083

Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol.* 2013 Apr 16;61(15):1601-6.

- Pastromas G, Spiliopoulos S, Katsanos K, Diamantopoulos A, Kitrou P, Karnabatidis D, Siablis D.** Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty. *Cardiovasc Intervent Radiol.* 2013 Feb 14. doi:10.1007/s00270-013-0577-3.
- Patel PA, Augoustides JG.** Progress in platelet medicine: focus on stent thrombosis and drug resistance. *J Cardiothorac Vasc Anesth.* 2010 Aug;24(4):722-7.
- Patti G, Mangiacapra F, Ricottini E, Cannatà A, Cavallari I, Vizzi V, D'Ambrosio A, Dicuonzo G, Di Sciascio G.** Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). *Am J Cardiol.* 2013 Jun 15;111(12):1739-44.
- Patti G, Nusca A.** Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty. *Circ J.* 2011;75(9):2050-1.
- Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G.** Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). *Am J Cardiol.* 2011 Apr 1; 107 (7):995-1000.
- Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G.** High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. *J Am Coll Cardiol.* 2011 Feb 15; 57 (7):771-8.
- Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G.** Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. *J Am Coll Cardiol.* 2008 Sep 30; 52 (14):1128-33.
- Paulu P, Osmancik P, Tousek P, Minarik M, Benesova L, Motovska Z, Bednar F, Kocka V, Widimsky P.** Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. *J Thromb Thrombolysis.* 2012 Oct 6. doi:10.1007/s11239-012-0813-8.
- Pendyala LK, Torguson R, Loh JP, Devaney JM, Chen F, Kitabata H, Minha S, Barbash IM, Suddath WO, Satler LF, Pichard AD, Waksman R.** Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. *Am Heart J.* 2013 Aug;166(2):266-72.
- Perakis PG, Yunus T, Long G, Cheema ZF, Hammond R, Shanley CJ.** Platelet function after cessation of chronic clopidogrel therapy. *Am Surg.* 2012 Jan;78(1):51-6.
- Perez de Prado A, Cuellas C, Diego A, de Miguel A, Samaniego B, Alonso-Orcajo N, Carbonell R, Pascual C, Fernandez-Vazquez F, Calabozo RG.** Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. *Thromb Res.* 2009 Dec; 124 (6):678-82.
- Pettersen AA, Arnesen H, Opstad TB, Seljeflot I.** The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. *Thromb J.* 2011 Mar 22; 9:4.
- Pinto Slottow TL, Bonello L, Gavini R, Beauzile P, Sushinsky SJ, Scheinowitz M, Kaneshige K, Xue Z, Torguson R, Tantry U, Pichard AD, Satler LF, Suddath WO, Kent K, Gurbel P, Waksman R.** Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. *Am J Cardiol.* 2009 Aug 15; 104 (4):525-30.
- Pittens CA, Bouman HJ, van Werkum JW, ten Berg JM, Hackeng CM.** Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. *J Thromb Haemost.* 2009 Nov; 7 (11):1929-32.

Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. *AJNR Am J Neuroradiol.* 2008 Feb; 29 (2):281-5.

Price MJ, Baker BA, Jakubowski JA, Li W, Heiselman DE, Angiolillo DJ. Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. *J Thromb Haemost* 2014; 12: 560–3.

Price MJ. Platelet reactivity after coronary stenting. *Lancet.* 2013 Aug 17;382(9892):583-4.

Price MJ. Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition. *JAMA.* 2012 Nov 7;308(17):1806-8.

Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. *J Am Coll Cardiol.* 2012 Jun 19;59(25):2338-43.

Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators. Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention: The GIFT (Genotype Information and Functional Testing) Study. *J Am Coll Cardiol.* 2012 May 29;59(22):1928-37.

Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. *Circulation.* 2011 Sep 6; 124 (10):1132-7.

Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA.* 2011 Mar 16; 305 (11):1097-105.

Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. *Am Heart J.* 2009 May; 157 (5):818-24, 824.e1.

Price MJ. Bedside Evaluation of Thienopyridine Antiplatelet Therapy. *Circulation* 2009;119;2625-2632.

Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. *Am J Cardiol.* 2009 May 15; 103 (10):1339-43.

Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. *Am J Cardiol.* 2008 Sep 15; 102 (6):790-5.

Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. *Eur Heart J.* 2008 Apr; 29 (8):992-1000.

Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. *Am J Cardiol.* 2006 Sep 1; 98 (5):681-4.

Rajendran S, Parikh D, Shugman I, French JK, Juergens CP. High on treatment platelet reactivity and stent thrombosis. *Heart Lung Circ.* 2011 Aug; 20 (8):525-31.

Reed GW, Cannon CP. Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. *J Am Coll Cardiol.* 2011 Dec 13;58(25):2640-1.

- Rho GJ, Shin WR, Kong TS, Kim MS, Lee CJ, Lee BH.** Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. *J Korean Neurosurg Soc.* 2011 Jul;50(1):40-4.
- Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.** Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. *Lancet.* 2012 Mar 28. doi:10.1016/S0140-6736(12)60161-5
- Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.** Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. *Circulation.* 2013 Aug 20;128(8):823-33.
- Rollini F, Tello-Montoliu A, Angiolillo DJ.** Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. *Platelets.* 2012;23(7):537-51.
- Rosengart TK, Romeiser JL, White LJ, Fratello A, Fallon E, Senzel L, Shroyer AL.** Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. *J Thorac Cardiovasc Surg.* 2013 Nov;146(5):1259-1266.
- Rudez G, Bouman HJ, van Werkum JW, Leebeek FW, Kruit A, Ruven HJ, ten Berg JM, de Maat MP, Hackeng CM.** Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. *Circ Cardiovasc Genet.* 2009 Oct; 2 (5):515-21.
- Ryu DS, Hong CK, Sim YS, Kim CH, Jung JY, Joo JY.** Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. *J Korean Neurosurg Soc.* 2010 Oct; 48 (4):319-24.
- Saia F, Marino M, Campo G, Valgimigli M, Guastaroba P, Taglieri N, Tondi S, Manari A, Guiducci V, Sangiorgio P, Varani E, Magnavacchi P, De Palma R, Marzocchi A.** Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). *Am J Cardiol.* 2013 Sep 15;112(6):792-8.
- Sakai N, Imamura H, Sakai C, Adachi H, Tani S, Ishikawa T, Mineharu Y, Ikeda H, Asai K, Inada T, Ogura T, Shibata T, Agawa Y, Shimizu K.** Advanced Endovascular Procedures for treating Intracranial Aneurysms. *Jpn J Neurosurg.* 2012; 21(12): 949-958.
- Sambu N, Hobson A, Curzen N.** "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility. *Platelets.* 2011; 22 (3):210-6.
- Satoh K.** Whole blood platelet function assay. *Jpn J Thromb Hemost* 2012; 23(3): 288-293.
- Saucedo JF, Angiolillo DJ, Deraad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; for the SWAP Investigators.** Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. *Thromb Haemost.* 2012 Dec 6;109(2). doi:10.1160/TH12-06-0378.
- Saw J, Madsen EH, Chan S, Maurer-Spurej E.** The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. *J Am Coll Cardiol.* 2008 Dec 2; 52 (23):1826-33.
- Saw J, Densem C, Walsh S, Jokhi P, Starovoytov A, Fox R, Wong G, Buller C, Ricci D, Mancini GB, Fung A.** The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. *JACC Cardiovasc Interv.* 2008 Dec; 1 (6):654-9.

- Seidel H, Rahman MM, Scharf RE.** Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. *Hamostaseologie*. 2011 Feb;31(1):41-51.
- Serebruany V, Pokov I, Kuliczowski W, Chesebro J, Badimon J.** Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. *Thromb Haemost*. 2008 Jul; 100 (1):76-82.
- Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF.** Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. *Am Heart J*. 2008 Jan; 155 (1):93.e1-7.
- Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR.** Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. *Postgrad Med J*. 2006 Jun; 82 (968):404-10.
- Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.** Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department. *Vasc Health Risk Manag*. 2013;9:187-93.
- Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD.** Evolving role of platelet function testing in coronary artery interventions. *Vasc Health Risk Manag*. 2012;8:65-75.
- Shim CY, Yoon SJ, Park S, Kim JS, Choi JR, Ko YG, Choi D, Ha JW, Jang Y, Chung N, Shim WH, Cho SY.** The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. *Int J Cardiol*. 2009 May 29; 134 (3):351-5.
- Short S, Kram B, Taylor S, Cheng J, Ali K, Vasquez D.** Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. *J Trauma Acute Care Surg*. 2013 Jun;74(6):1419-24.
- Sibbing D, Byrne RA, Bernlochner I, Kastrati A.** High platelet reactivity and clinical outcome - fact and fiction. *Thromb Haemost*. 2011 Aug;106(2):191-202.
- Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).** Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality. *JACC Cardiovasc Interv*. 2013 Nov;6(11):1111-28.
- Siller-Matula JM, Jilma B.** Why have studies of tailored anti-platelet therapy failed so far? *Thromb Haemost*. 2013 Oct;110(4):628-31.
- Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA, Bellemain-Appaix A, Barthélémy O, Beygui F, Collet JP, Montalescot G.** High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. *Eur Heart J*. 2011 Nov 7. doi:10.1093/eurheartj/ehr407
- Sinhal AR, Aylward PE.** New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. *Clin Ther*. 2013 Aug;35(8):1064-8.
- Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R.** Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. *Clin Ther*. 2010 Feb; 32 (2):365-79.
- Smith SM, Judge HM, Peters G, Storey RF.** Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. *Platelets*. 2004 Dec; 15 (8):465-74.
- Sobieraj-Teague M, Eikelboom JW.** Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease. *Future Cardiol*. 2010 May;6(3):289-99.

- Song TJ, Suh SH, Min PK, Kim DJ, Kim BM, Heo JH, Kim YD, Lee KY.** The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting. *Yonsei Med J.* 2013 Mar 1;54(2):288-94.
- Sorkin GC, Dumont TM, Wach MM, Eller JL, Mokin M, Natarajan SK, Baxter MS, Snyder KV, Levy EI, Hopkins LN, Siddiqui AH.** Carotid artery stenting outcomes: do they correlate with antiplatelet response assays? *J Neurointerv Surg.* 2013 Jun 22. doi:10.1136/neurintsurg-2013-010771.
- Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D.** Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. *J Am Coll Cardiol.* 2013 Jun 18;61(24):2428-34.
- Spiliopoulos S, Kassimis G, Hatzidakis A, Krokidis M.** High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures. *Cardiovasc Intervent Radiol.* 2013 Jul 30.
- Stegnar M.** Platelet function tests and resistance to antiplatelet therapy. *Srp Arh Celok Lek.* 2010 Jan; 138 Suppl 1:59-63.
- Steiner S, Moertl D.** Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. *Expert Rev Cardiovasc Ther.* 2013 Aug;11(8):975-84.
- Sternberg Z, Ching M, Sawyer RN, Chichelli T, Li F, Janicke D, Radovic V, Mehta B, Farooq O, Munschauer FE.** Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen. *J Stroke Cerebrovasc Dis.* 2011 Dec 28. doi:10.1016/j.jstrokecerebrovasdis.2011.11.009.
- Stetler WR, Chaudhary N, Thompson BG, Gemmete JJ, Maher CO, Pandey AS.** Prasugrel is effective and safe for neurointerventional procedures. *J Neurointerv Surg.* 2012 May 22. doi:10.1136/neurintsurg-2012-010302.
- Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators.** Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet.* 2013 Aug 17;382(9892):614-23.
- Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, Tantry U, Gurbel PA.** Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. *J Thromb Haemost.* 2011 Sep; 9 (9):1730-7.
- Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L.** Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATElet inhibition and patient Outcomes) PLATELET substudy. *J Am Coll Cardiol.* 2010 Oct 26; 56 (18):1456-62.
- Suh JW, Kim CH, Oh IY, Yoon CH, Kim KI, Cho YS, Youn TJ, Chae IH, Choi DJ.** Effect of Tailored Antiplatelet Therapy on Periprocedural Myonecrosis in Patients With Diabetes Mellitus (from the DM-VerifyNow Trial). *Am J Cardiol.* 2012 Sep 19. doi:10.1016/j.amjcard.2012.08.009.
- Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS.** Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. *J Am Coll Cardiol.* 2011 Jan 18; 57 (3):280-9.
- Sumaya W, Daly RL, Mehra S, Dhutia AJ, Howgego KE, Ecob R, Judge HM, Morton AC, Storey RF.** Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay. *Thromb Haemost.* 2013 Jan 10;109(3). doi:10.1160/TH12-10-0718.

- Suryadevara S, Ueno M, Tello-Montoliu A, Ferreira JL, Desai B, Rollini F, Box LC, Zenni M, Guzman LA, Bass TA, Angiolillo DJ.** Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. *Thromb Haemost.* 2012 Jul 10;108(4).
- Tähtinen OI, Manninen HI, Vanninen RL, Rautio R, Haapanen A, Seppänen J, Niskakangas T, Rinne J, Keski-Nisula L.** Stent-assisted embolization of recurrent or residual intracranial aneurysms. *Neuroradiology.* 2013 Oct;55(10):1221-31.
- Tanaka KA, Dietrich W.** Is it time to implement preoperative platelet function testing before invasive procedures? *Br J Anaesth.* 2011 Dec;107(6):842-3.
- Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity.** Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. *J Am Coll Cardiol.* 2013 Dec 17;62(24):2261-73.
- Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA.** First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. *Circ Cardiovasc Genet.* 2010 Dec; 3 (6):556-66.
- Taylor G, Osinski D, Thevenin A, Devys JM.** Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? *J Trauma Acute Care Surg.* 2013 May;74(5):1367-9.
- Tazaki J, Jinnai T, Tada T, Kato Y, Makiyama T, Ikeda T, Yamane K, Naruse Y, Takahashi K, Watanabe H, Kimura T, Horiuchi H.** Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. *J Atheroscler Thromb.* 2012;19(2):186-93.
- Tello-Montoliu A, Tomasello SD, Ferreira JL, Ueno M, Seecheran N, Desai B, Kodali M, Charlton RK, Box LC, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.** Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. *J Am Coll Cardiol.* 2012 May 8;59(19):1681-7.
- Toma C, Zahr F, Moguilanski D, Grate S, Semaan RW, Lemieux N, Lee JS, Cortese-Hassett A, Mulukutla S, Rao SV, Marroquin OC.** Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. *Am J Cardiol.* 2012 Apr 15;109(8):1148-53.
- Tousek P, Kocka V, Sulzenko J, Bednar F, Linkova H, Widimsky P.** Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. *Biomed Res Int.* 2013;2013:386074. doi: 10.1155/2013/386074.
- Tousoulis D, Paroutoglou IP, Papageorgiou N, Charakida M, Stefanadis C.** Recent therapeutic approaches to platelet activation in coronary artery disease. *Pharmacol Ther.* 2010 Aug;127(2):108-20.
- Trenk D, Zolk O, Fromm MF, Neumann FJ, Hochholzer W.** Personalizing Antiplatelet Therapy With Clopidogrel. *Clin Pharmacol Ther.* 2012 Sep 5. doi:10.1038/clpt.2012.133.
- Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ.** A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. *J Am Coll Cardiol.* 2012 Apr 9. doi:10.1016/j.jacc.2012.02.026.
- Tselepis AD, Gerotziapas G, Andrikopoulos G, Anninos H, Vardas P.** Mechanisms of platelet activation and modification of response to antiplatelet agents. *Hellenic J Cardiol.* 2011 Mar-Apr;52(2):128-40.
- Tunggal P, Ng FH, Lam KF, Chan FK, Lau YK.** Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. *Am Heart J.* 2011 Nov;162(5):870-4.

Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. *Cardiovasc Ther.* 2011 Dec;29(6):e100-11.

Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, Capranzano P, Kodali M, Dharmashankar K, Charlton RK, Bass TA, Angiolillo DJ. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. *JACC Cardiovasc Interv.* 2012 Mar;5(3):293-300.

Ueno M, Ferreiro JL, Tomasello SD, Tello-Montoliu A, Capodanno D, Seecheran N, Kodali M, Dharmashankar K, Desai B, Charlton RK, Bass TA, Angiolillo DJ. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. *JACC Cardiovasc Interv.* 2011 Aug; 4 (8):905-12.

Umemura K. Genetic Polymorphism of CYP2C19 Affects Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects. *Jpn J Clin Pharmacol Ther.* 2009 Nov; 40(6):261-5.

Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R, Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. *Circulation.* 2009 Jun 30; 119 (25):3215-22.

Van Der Heyden J, Van Werkum J, Hackeng CM, Kelder JC, Breet NJ, Deneer VH, Ackerstaff RG, Tromp SC, De Vries JP, Vos JA, Suttorp MJ, Elsenberg EH, Van Neerven D, Schonewille WJ, Wolters F, Ten Berg JM. High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial. *J Cardiovasc Surg (Torino).* 2012 Nov 8.;53:1-11.

van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. *Platelets.* 2008 Nov; 19 (7):479-88.

van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. *J Thromb Haemost.* 2006 Nov; 4 (11):2516-8.

Varenhorst C, Koul S, Erlinge D, Lagerqvist B, Siegbahn A, Wallentin L, James S. Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. *Am Heart J.* 2011 Aug; 162 (2):363-71.

Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. *Eur Heart J.* 2009 Jul; 30 (14):1744-52.

Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. *Am Heart J.* 2009 Mar; 157 (3):562.e1-9.

Vavuranakis M, Vrachatis DA, Papaioannou TG, Archontakis S, Kalogeras KI, Kariori MG, Gafou A, Moldovan C, Tzamalidis P, Stefanadis C. Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention - Impact on intracoronary thrombus burden and myocardial perfusion-. *Circ J.* 2011 Aug 25; 75 (9):2105-12.

Viswanathan GN, Marshall SM, Schechter CB, Balasubramaniam K, Badimon JJ, Zaman AG. Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. *Thromb Haemost.* 2012 Nov;108(5):937-45.

- Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.** Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. *JACC Cardiovasc Interv.* 2013 Nov;6(11):1166-75.
- Voisin S, Bongard V, Tidjane MA, Lhermusier T, Carrié D, Sié P.** Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. *Thromb Haemost.* 2011 Aug; 106 (2):227-9.
- von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schömig A, Kastrati A.** Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. *Blood Coagul Fibrinolysis.* 2010 Jan; 21 (1):46-52.
- von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schömig A.** A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. *Eur Heart J.* 2007 Aug; 28 (15):1814-9.
- von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schömig A, Kastrati A.** Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. *Thromb Haemost.* 2006 May; 95 (5):910-1.
- Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, Moser BA, Zhou C, Brown P, James S, Winters KJ, Erlinge D.** Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. *J Thromb Thrombolysis.* 2013 Sep 17. doi:10.1007/s11239-013-0987-8
- Wiviott SD, Hochholzer W.** On-clopidogrel platelet reactivity: a target in sight? *J Am Coll Cardiol.* 2011 Nov 1;58(19):1955-7.
- Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators.** Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. *Circulation.* 2007 Dec 18; 116 (25):2923-32.
- Wong CK.** Measuring Platelet Reactivity after Clopidogrel – Has it Reached the End of the Road? *Cardiol Pharmacol.* 2013; 2:e105. doi:10.4172/cpo.1000e105
- Woo JS, Kim W, Lee SR, Jung KH, Kim WS, Lew JH, Lee TW, Lim CK.** Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study. *Am Heart J.* 2011 Dec; 162 (6):1018-25.
- Woo KS, Kim BR, Kim JE, Goh RY, Yu LH, Kim MH, Han JY.** Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. *Korean J Lab Med.* 2010 Oct; 30 (5):460-8.
- Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, Ataga KI, Knupp CL, McMahon LE, Strouse JJ, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Riesmeyer JS, Winters KJ.** A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. *J Hematol Oncol.* 2013 Feb 17;6(1):17. doi:10.1186/1756-8722-6-17.
- Xanthopoulou I, Stavrou EF, Kassimis G, Goudas P, Alexopoulos D.** Resistance to high-maintenance dose of prasugrel treated by ticagrelor: A case report. *Platelets.* 2012 May 30. doi:10.3109/09537104.2012.682104.

Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, Murata M. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. *Thromb Res.* 2013 Aug;132(2):263-70.

Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. *Platelets.* 2013;24(5):352-61.

Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, Jinnai T, Ikeda T, Shirakawa R, Kimura T, Horiuchi H. Effects of PPIs and an H2 blocker on the Antiplatelet Function of Clopidogrel in Japanese Patients under Dual Antiplatelet Therapy. *J Atheroscler Thromb.* 2012 Apr 4. doi:10.5551/jat.11601

Yang TH, Jin HY, Choi KN, Do U, Kim HJ, Chung SR, Seo JS, Jang JS, Kim DK, Kim DS. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. *Int J Cardiol.* 2012 Oct 26. doi:10.1016/j.ijcard.2012.09.093.

Yang TH, Kim DI, Kim DK, Jang JS, Kim U, Seol SH, Kim DK, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Nam CW, Hur SH, Kim KB, Kim DS. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. *Korean J Intern Med.* 2011 Jun; 26 (2):145-52.

Yu KS, Park KW, Kelly RP, Gu N, Payne C, Small DS, Choi HC, Kawakatsu E, Pinton P. Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. *J Cardiovasc Pharmacol.* 2013 Jul;62(1):72-7.

Yu LH, Kim MH, Zhang HZ, Park JS, Park TH, Kim YD, Cha KS, Han JY. Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome. *Korean Circ J.* 2012 Jun;42(6):382-9.

Yun KH, Rhee SJ, Park HY, Yoo NJ, Kim NH, Oh SK, Jeong JW. Effects of omeprazole on the antiplatelet activity of clopidogrel. *Int Heart J.* 2010 Jan; 51 (1):13-6.

Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, Sartori S, Small DS, Jakubowski JA, Fuster V, Badimon JJ. Platelet Function Normalization after a Prasugrel Loading Dose: Time-dependent Effect of Platelet Supplementation. *J Thromb Haemost.* 2012 Nov 8. doi:10.1111/jth.12058.

Zhang HZ, Kim MH, Han JY, Jeong YH. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI. *Platelets.* 2013 Aug 23. doi: 10.3109/09537104.2013.815340.

Zhang HZ, Kim MH, Jeong YH. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. *Platelets.* 2013 Aug 23. doi: 10.3109/09537104.2013.815341.

Supporting Clinical Guidelines

Ferraris, VA, Saha SP, Oestreich JH, et al. 2012 Update to The Society of Thoracic Surgeons (STS) Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. *Annals of Thoracic Surgery* 94.5 (2012): 1763.

Ferraris, VA, Brown JR, Despotis GJ, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. *Annals of Thoracic Surgery* 91.3 (2011): 947.

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation. *European Heart Journal* (2015): 33.

Accriva Diagnostics, Inc. | 6260 Sequence Drive | San Diego, CA 92121 USA
Tel: 858.263.2300 | Toll-Free: 800.631.5945 | www.accriva.com

Accriva
d i a g n o s t i c s

MVN0014 1215